WO1998007708A1 - Isoxazoline derivatives useful as antimicrobials - Google Patents

Isoxazoline derivatives useful as antimicrobials Download PDF

Info

Publication number
WO1998007708A1
WO1998007708A1 PCT/US1997/013934 US9713934W WO9807708A1 WO 1998007708 A1 WO1998007708 A1 WO 1998007708A1 US 9713934 W US9713934 W US 9713934W WO 9807708 A1 WO9807708 A1 WO 9807708A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
optionally substituted
alkyl
phenyl
compound
Prior art date
Application number
PCT/US1997/013934
Other languages
French (fr)
Inventor
Michael R. Barbachyn
Richard C. Thomas
Gary J. Cleek
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Priority to JP10510781A priority Critical patent/JP2000516245A/en
Priority to DE69716925T priority patent/DE69716925T2/en
Priority to EP97937156A priority patent/EP0920421B1/en
Priority to SI9730449T priority patent/SI0920421T1/en
Priority to DK97937156T priority patent/DK0920421T3/en
Priority to AU39736/97A priority patent/AU3973697A/en
Priority to AT97937156T priority patent/ATE227277T1/en
Publication of WO1998007708A1 publication Critical patent/WO1998007708A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Definitions

  • This invention describes isoxazoline derivatives which are effective as antibacterial agents.
  • the compounds of the invention are novel and distinct from all other oxazolidinones in that the usual oxazolidinone rings are replaced by an isoxazoline moiety. These compounds have antibacterial activity comparable to the corresponding oxazolidinones. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply- resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium a ⁇ ium.
  • R 96 is a) an aromatic moiety having 6 to 10 carbon atoms, b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) which can in turn be substituted with one or three -N0 2 , CF 3 , halo, -CN, OH, phenyl, C ⁇ g alkyl, C 1 _ 5 alkoxy, or C 1 5 acyl,
  • C 2 _ 5 alkynyl refers to at least one triple bond alkynyl group having two to five, two to eight, or two to ten carbon atoms respectively such as, for example, ethynyl, propynyl, butynyl, pentynyl, pentdiynyl, hexynyl, hexdiynyl, heptynyl, heptdiynyl, octynyl, octdiynyl, octatriynyl, nonynyl, nonediynyl, nonatriynyl and their isomeric forms thereof.
  • the reaction is diluted with ethyl acetate (100 mL) and water (50 mL).
  • the organic phase is separated and the aqueous phase is extracted with methylene chloride (4X50 mL).
  • the organic extracts are combined, dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (98/2).
  • the compound of Example 1, Step 1 can be prepared enantiomerically pure by a procedure from Ukaji, Y.; Sada, K.; Inomata, K. Chem. Lett. 1993, pp 1847-1580.
  • the reaction is diluted with ethyl acetate (100 mL) and water (50 mL).
  • the organic phase is separated, extracted with water (5 X 50 mL), dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with methylene chloride/methanol (99/1).

Abstract

The present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof wherein A and R1 are as defined in the claims which are antibacterial agents.

Description

ISOXAZOLINE DERIVATIVES USEFUL AS ANTIMICROBIALS
FIELD OF THE INVENTION The present invention relates to novel isoxazoline derivatives or pharmaceutically acceptable salts thereof which are useful as antibacterial agents.
BACKGROUND OF THE INVENTION Antibacterial agents such as oxazolidinones are a class of known orally- active, synthetic antibacterial agents and there are numerous references in the art disclosing a variety of oxazolidinone derivatives. For example, U.S. Patent Nos. 4,705,799 and 5,523,403 and European Patent Application 0,316,594 disclose substituted phenyl-2-oxazolidinones, including the sulfides, sulfoxides, sulfones, sulfonamides, nitriles, acetamides and a tropone ring. U.S. Patent Nos. 4,948,801; 5,254,577 and 5,130,316 disclose arylbenzene oxazolidinyl compounds, wherein the aryl includes the (un)substituted phenyl and pyridyl groups. European Patent
Applications 0,697,412; 0,694,544; 0,694,543 and 0,693,491 disclose 5 to 9-membered heteroaryl-oxazolidinones having one to three atoms selected from the group consisting of sulfur, nitrogen and oxygen.
This invention describes isoxazoline derivatives which are effective as antibacterial agents. The compounds of the invention are novel and distinct from all other oxazolidinones in that the usual oxazolidinone rings are replaced by an isoxazoline moiety. These compounds have antibacterial activity comparable to the corresponding oxazolidinones. They are effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply- resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium aυium.
INFORMATION DISCLOSURE U.S. Patent No. 4,283,403 discloses 3-aryl-2-isoxazolines useful for the protection of plants from disease.
Danish Patent No. 2,725,763 discloses substituted 2-isoxazolines which is fungicidal against phytophthora infestation on tomatoes. The compounds also show antibacterial activity. U.S. Patent No. 3,769,295 discloses nitrofuryl derivatives of 5-substituted isoxazolines useful as antimicrobial agents. WO 95/14680 Al discloses 3-aryl-2-isoxazolines which is useful in inhibiting PDEjy, the treatment of inflammatory diseases and the treatment of AIDs, asthma, arthritis, etc.
S. S. Ghabrial, et al., Acta Chemica Scandinavica, B 41, pp. 426-434 (1987) discloses the synthesis of heteroaromatic compounds via the isoxazoline route.
SUMMARY OF THE INVENTION The present invention provides new antibacterial compounds of the formula I
Figure imgf000004_0001
I or pharmaceutical acceptable salts thereof wherein:
Figure imgf000004_0004
A is
Figure imgf000004_0002
Figure imgf000004_0003
d) a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom, wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R^g, e) a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R55, f) a β-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three R55,
Figure imgf000005_0001
Figure imgf000005_0002
g) R2 and R3 taken together are -0-(CH2)h-0-;
R is a) -S(=0)i R4, b) -S(=0)2-N=S(0)jR5R6, c) -SC(=0)R7, d) -C(=0)R8, e) -C(=0)R9, f) -C(=O)NR10Rn, g) -C(=NR12)R8, h) -C(R8)(Rn)-OR13, i) -C(R9)(Rn)-OR13> j) -C(R8)(Rn)-OC(=0)R13, k) -C(R9)(R11)-OC(=0)R13,
1) -NR10Rn, m) -N(R10)-C(=O)R7, n) -N(R10)-S(=O)iR7, o) -C(OR14)(OR15)R8, p) -C(R8XR16)-NR10Rπ, or q) Cj 8 alkyl substituted with one or more =0 other than at alpha position, -S(=0)jR17, -NRJQR^, C2_5 alkenyl, or C2 g alkynyl;
R4 is a) C1 4 alkyl optionally substituted with one or more halos, OH, CN, NR10Rn, or -C02R13,
Figure imgf000006_0001
a) H, or b) C^ alkyl optionally substituted with one or more halos, or C3.g cycloalkyl;
R9 is C 1-4 alkyl substituted with one or more a) -S(=0)R17,
Figure imgf000007_0002
a) H, or b) C1 alkyl;
R14 and R^ at each occurrence are the same or different and are a) Cj.4 alkyl, or b) R1 and R15 taken together are -(CH)j-; R16 is a) H, b) C1-4 alkyl, or c) C3.8 cycloalkyl; R17 is a)
Figure imgf000007_0001
alkyl, or b) C3 8 cycloalkyl;
R18 is a) H, b) CM alkyl, c) C2_4 alkenyl, d) C3.4 cycloalkyl, e) "OR 13- or f) -NR21R22;
R19 is
Figure imgf000008_0003
R2 is a physiologically acceptable cation;
R 1 and R22 at each occurrence are the same or different and are a) H, b) C1.4 alkyl, or c) -NR21R22 taken together are -(CH2)m-; wherein R23 and R24 at each occurrence are the same or different and are a) H,
Figure imgf000008_0004
Q is a)
3D-
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0003
Figure imgf000009_0004
j) S^^-X
Figure imgf000009_0005
k)
Figure imgf000010_0001
m) a diazinyl group optionally substituted with X and Y, n) a triazinyl group optionally substituted with X and Y, o) a quinolinyl group optionally substituted with X and Y, p) a quinoxalinyl group optionally substituted with X and Y, or q) a naphthyridinyl group optionally substituted with X and Y; B is an unsaturated 4-atom linker having one nitrogen and three carbons; M is a) H, b) C1 alkyl, c) C3,8 cycloalkyl, d) -(CH2)mOR13( or e) -(CH2)h-NR21R22; is a) O, b) S, or c) NM; W is
Y is
Figure imgf000010_0002
X is a) H, b) -CN, c) OR27, d) halo, e) N02,
Figure imgf000011_0001
alpha position, -S(=0)jR17, -NR27R28, C2 5 alkenyl, C2_5 alkynyl, or C3.8 cycloalkyl; R4, R5, R6, R7, R13, R14, Rι5, Rj^g, and R17 are the same as defined above; R25 is a) H, b) C1 8 alkyl optionally substituted with one or more halos, C _8 cycloalkyl, C1-4 alkyl substituted with one or more of -S(=0)jR17, -OR13, or OC(=0)R13, NR27R28, or c) C2.5 alkenyl optionally substituted with CHO, or C02R13; R26 is a) R28, or b) NR27N28; R27 and R28 at each occurrence are the same or different and are a) H, b) C^g alkyl, c) C3_8 cycloalkyl, d) -(CH2)mOR13> e) -(CH2)h-NR21R22, or f) R27 and R28 taken together are -(CH2)20(CH2)2-, -(CH2)hCH(COR7)-, or -(CH2)2N(CH2)2(R7);
Figure imgf000012_0001
a) H, b) C ^Q alkyl optionally substituted with one or more halos, or c) C^ alkyl optionally substituted with one or more OH, or C^g alkoxy; wherein E is a) NR39, b) -S(=O)j, or c) O;
Figure imgf000012_0002
a) H, b) C^g alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CH2)q-aryl, d) -C02R4Q, e) -COR41, f -C(=O)-(CH2)q-C(=O)R40, g) -S(=0)2-C1.g alkyl, h) -S(=0)2-(CH2)q-aryl, or i) -(C=0)j-Het; R4fJ is a) H, b) C1_6 alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CH2)q-aryl, or d) -(CH2)q-OR42; R41 is a) C-^g alkyl optionally substituted with one or more OH, halo, or -CN, b) -(CH2)q-aryl, or
Figure imgf000013_0002
ections a to c can be optionally substituted with one or more halo, -CN, OH, SH, C^g alkyl, C1 6 alkoxy, or C^g alkylthio; wherein R43 is a) H, b) Cλ_2 alkyl, c) F, or d) OH; R44 is a) H, b) CFg, c) C1 3 alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) R44 and R45 taken together are a 5-, 6-, or 7-membered ring of the formula,
Figure imgf000013_0001
or f) R44 and R4g taken together are -(CH2)ιt-, when R46 is an electron- withdrawing group; R45 and R46 at each occurrence are the same or different and are a) an electron -withdrawing group, b) H, c) CF3, d) Cj^ alkyl optionally substituted with one halo, e) phenyl, provided at least one of R45 or R46 are an electron- withdrawing group, or f) R45 and R46 taken together are a 5-, 6-, 7-membered ring of the formula
Figure imgf000014_0001
U is a) CH2, b) 0, c) S, or d) NR47;
R47 is a) H, or b) Cl δ alkyl; wherein R48 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, 0 CF3, g) -N02, h) Cj. alkoxy, i) Cj alkoxycarbonyl, j) Cj.g alkythio, k) C^g acyl,
1) -NR49 R50, m) Cj.g alkyl optionally substituted with OH, C^g alkoxy, C^5 acyl, or
-NR49R50, n) C2_g alkenylphenyl optionally substituted with one or two Rg^, o) phenyl optionally substituted with one or two R51, p) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, optionally substituted with one or two R51, or
Figure imgf000014_0002
R49 and R50 at each occurrence are the same or different and are a) H, b) CL_4 alkyl, c) C5.g cycloalkyl, or i d) R49 and R50 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and 0, and can in turn be optionally substituted with, including on the further nitrogen atom, C1 3 alkyl, or Cj.-j acyl;
Figure imgf000015_0001
wherein R55 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) -N02, h) C1 6 alkoxy, i) Cj.g alkoxycarbonyl, j) Cj.g alkythio, k) C^g acyl,
1) -NRgg R57, m) C^ alkyl optionally substituted with OH, Cj 5 alkoxy, C 5 acyl, or -NR56R57) n) C2.8 alkenylphenyl optionally substituted with one or two R58, o) phenyl optionally substituted with one or two R58, p) a 5- or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, optionally substituted with one or two R58, or
Figure imgf000016_0001
Rgg and R57 at each occurrence are the same or different and are a) H, b) formyl, c) C1 alkyl, d) Cλ_4 acyl, e) phenyl, f) C3_g cycloalkyl, or g) Rgg and Rg7 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C^ alkyl, or C1_3 acyl; R58 is
Figure imgf000017_0002
Figure imgf000017_0001
substituted with OH, azido, Cj g alkoxy, C1 5 acyl, -NRggRgg, -SR67, -0-S02R68, or
R 69- y- NH-CO-O-
n) -C(=0)NR59 R60, o) -NR56Rg7, p) -N(R59)(-S02R54), q) -SO2-NR59R60, r) -S(=0)iR54, s) -CH=N-R61, or t) -CH(OH)-S03R64;
R54 is the same as defined above; Rg9 and R60 at each occurrence are the same or different and are a) H,
Figure imgf000017_0003
e) -NH-C(=NH)-NR62Rg3; R62 and R63 at each occurrence are the same or different and are a) H, or b) C1-4 alkyl optionally substituted with phenyl or pyridyl; R64 is a) H, or b) a sodium ion;
Rgg and Rg at each occurrence are the same or different and are a) H, b) formyl, c) C alkyl, d) Cw acyl, e) phenyl, f) C3.6 cycloalkyl, g) R and R66 taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C1 3 alkyl, or C^ acyl, h) -P(O)(OR70)(OR71), or i) -S02-R72;
Rg is
Figure imgf000018_0001
R68 is Cj.3 alkyl; R69 is a) Cj.g alkoxycarbonyl, or b) carboxyl;
R70 and R71 at each occurrence are the same or different and are a) H, or b) Cj.3 alkyl;
R o is a) methyl, b) phenyl, or c) tolyl; wherein K is a) 0, or b) S; R73, R74, R75, R76, and R77 at each occurrence are the same or different and are a) H, b) carboxyl, c) halo, d) -CN, e) mercapto, f) formyl, g) CF3, h) -N02, i) Cj.g alkoxy, j) Cj g alkoxycarbonyl, k) C-^g alkythio, 1) Cj.g acyl, m) -NR78 R79, n) C^g alkyl optionally substituted with OH, C1 5 alkoxy, C^ 5 acyl, -NR78R79, -N(phenyl)(CH2-CH2-OH), -0-CH(CH3)(OCH2CH3), or -0-phenyl-[para-NHC(=0)CH3], o) C2_8 alkenylphenyl optionally substituted with Rg^ p) phenyl optionally substituted with R51, or q) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, optionally substituted with R51; R is the same as defined above; R78 and R79 at each occurrence are the same or different and are a) H, b) Cl 4 alkyl, c) phenyl, or d) R78 and R79 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, C1 3 alkyl, or C^g acyl; wherein T is a) O, b) S, or c) S02;
R75, R76, and R77 are the same as defined above; R80 is a) H, b) formyl, c) carboxyl, d) Cj.g alkoxycarbonyl, e) C^g alkyl, f) C2 8 alkenyl, wherein the substituents (e) and (f) can be optionally substituted with
OH, halo, C g alkoxy, C1 6 acyl, C1 6 alkylthio or C^g alkoxycarbonyl, or phenyl optionally substituted with halo, g) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, C^g alkyl, C^ alkoxy, C1 6 acyl, C^ alkylthio, or C^ g alkoxycarbonyl, h) -NR81R82, i) -ORQQ, j) -S(=0)fR91, k) -S02-N(R92)(R93), or 1) a radical of the following formulas:
Figure imgf000021_0001
NNHH. oα-
R83RΘ4N— ^ SN — -
RfJ7
HN N— R96-(CH2)t_N N— R87-N' ' -
R8 7 d R82 at each occurrence are the same or different and are a) H, b) C3_ cycloalkyl, c) phenyl, d) C^g acyl, e) C18 alkyl optionally substituted with OH, Cμg alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, phenyl optionally substituted with OH, CF3, halo, -N02, Ct_4 alkoxy, -NR83Rg4, or
Figure imgf000021_0002
Figure imgf000021_0003
) vr~^W-(CH2)t-
V is a) O, b) CH2, or c) NR87;
Rg3 and Rg4 at each occurrence are the same or different and are a) H, or b)
Figure imgf000022_0001
alkyl;
Rgg is a) OH, b) C1-4 alkoxy, or c) -NR88 R89; R 86 is a) H, or b) C^-7 alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH,
-C(=0)-NH2, -C02H, or -C(=NH)-NH2;
Figure imgf000022_0002
a) Cj^ alkyl optionally substituted with C-^g alkoxy or Cj. hydroxy,
C3 6 cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -N02, CF3, halo, -CN, OH, Cj.g alkyl, C-^g alkoxy, or C^g acyl;
Figure imgf000023_0001
c) phenyl, or d) pyridyl;
R91 is a) Cj^g alkyl, b) c2-16 a^eny-< wherein the substituents (a) and (b) can be optionally substituted with Cj.g alkoxycarbonyl, or a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, c) an aromatic moiety having 6 to 10 carbon atoms, or d) a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, C1 6 alkyl, C1_6 alkoxy, Cj.g acyl, Cj.g alkylthio, or C1 6 alkoxycarbonyl; RQ2 and R9 at each occurrence are the same or different and are a) H, b) phenyl, c) Cj^. alkyl, or d) benzyl;
Rq4 and Rgg at each occurrence are the same or different and are a) H, b) OH, c) Cj.g alkyl optionally substituted with -NRg3 R8 , or d) Rg4 and R95 taken together are =0; R96 is a) an aromatic moiety having 6 to 10 carbon atoms, b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) which can in turn be substituted with one or three -N02, CF3, halo, -CN, OH, phenyl, C^g alkyl, C1_5 alkoxy, or C1 5 acyl,
Figure imgf000024_0001
The compounds of the present invention have antibacterial activity. They are effective against a number of human and veterinary pathogens.
DETAILED DESCRIPTION OF THE INVENTION
For the purpose of the present invention, the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Cj ,• defines the number of carbon atoms present from the integer "i" to the integer "j", inclusive. Thus, Cj_4 alkyl refers to alkyl of 1-4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl and isomeric forms thereof.
The terms "C^ alkyl", "Cj.g alkyl", "Cμ alkyl", "C^g alkyl", "C^g alkyl", "Ci 8 alkyl", and "C^jg alkyl" refer to an alkyl group having one to two, one to three, one to four, one to five, one to six, one to eight, or one to sixteen carbon atoms respectively such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and their isomeric forms thereof.
The terms "C2.4 alkenyl", "C2_5 alkenyl", "C2_8 alkenyl", "C2.14 alkenyl" and "C2_ig alkenyl" refer to at least one double bond alkenyl group having two to four, two to five, two to eight, two to fourteen, or two to sixteen carbon atoms, respectively such as, for example, ethenyl, propenyl, butenyl, pentenyl, pentdienyl, hexenyl, hexdienyl, heptenyl, heptdienyl, octenyl, octdienyl, octatrienyl, nonenyl, nonedienyl, nonatrienyl, undecenyl, undecdienyl, dodecenyl, tridecenyl, tetradecenyl and their isomeric forms thereof.
The terms "C2_5 alkynyl", "C2.8 alkynyl", and "C2_10 alkynyl" refer to at least one triple bond alkynyl group having two to five, two to eight, or two to ten carbon atoms respectively such as, for example, ethynyl, propynyl, butynyl, pentynyl, pentdiynyl, hexynyl, hexdiynyl, heptynyl, heptdiynyl, octynyl, octdiynyl, octatriynyl, nonynyl, nonediynyl, nonatriynyl and their isomeric forms thereof.
The terms "C3.4 cycloalkyl", "C3.6 cycloalkyl", "C5.6 cycloalkyl", and "C3_8 cycloalkyl" refer to a cycloalkyl having three to four, three to six, five to six, or three to eight carbon atoms respectively such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and their isomeric forms thereof.
The terms "Cw alkoxy", "Cj.g alkoxy", and "C^ alkoxy" refer to an alkyl group having one to four, one to six, or one to eight carbon atoms respectively attached to an oxygen atom such as, for example, methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, heptyloxy, or octyloxy and their isomeric forms thereof.
The terms "C1.6 alkylamino", and "C^ alkylamino" refer to an alkyl group having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, methylamino, ethylamino, propylamino, butylamino, pentylamino, hexylamino, heptylamino, or octoylamino and their isomeric forms thereof.
The terms "C^ dialkylamino", and "C^ dialkylamino" refer to two alkyl groups having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, dimethylamino, methylethylamino, diethylamino, dipropylamino, methypropyiamino, ethylpropylamino, dibutylamino, dipentylamino, dihexylamino, methylhecylamino, diheptylamino, or dioctoylamino and their isomeric forms thereof.
The terms "C^g acyl", MC1-4 acyl", "C,.5 acyl", "Cj.g acyl", "C1.8 acyl", and "C2.8 acyl" refer to a carbonyl group having an alkyl group of one to three, one to four, one to five, one to six, one to eight, or two to eight carbon atoms.
The terms "Cj^ alkoxycarbonyl", "C1_6 alkoxycarbonyl", and "C1_8 alkoxycarbonyl" refer to an ester group having an alkyl group of one to four, one to six, or one to eight carbon atoms.
The term "C1 8 alkyl phenyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical.
The term "C2.8 alkenyl phenyl" refers to a at least one double bond alkenyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical. The term "C1 8 alkyl pyridyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one pyridyl radical.
The term "C1 hydroxyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a hydroxy group. The term "C1 8 alkylsulfonyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a S02 moiety.
The term "Cj.g alkylthio" refers to an alkyl group having one to six carbon atoms and isomeric forms thereof attached to a sulfur atom.
The term "Het" refers to 5 to 10 membered saturated, unsaturated or aromatic heterocyclic rings containing one or more oxygen, nitrogen, and sulfur forming such groups as, for example, pyridine, thiophene, furan, pyrazoline, pyrimi- dine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3- pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3- isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1- phthalazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2- oxazolyl, 5-oxazolyl, 4,5,-dihydrooxazole, 1,2,3-oxathiole, 1,2,3-oxadiazole, 1,2,4- oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3- isothiazole, 4-isothiazole, 5-isothiazole, 2-indolyl, 3-indolyl, 3-indazolyl, 2- benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, benzoisothiazole, benzisoxazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1,2,3,-oxathiazole-l-oxide, 1,2,4- oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, 5-oxo-l,2,4-oxadiazol-3-yl, l,2,4-thiadiazol-3-yl, l,2,4-thiadiazol-5-yl, 3-oxo-l,2,4-thiadiazol-5-yl, l,3,4-thiadiazol-5-yl, 2-oxo-l,3,4- thiadiazol-5-yl, l,2,4-triazol-3-yl, l,2,4-triazol-5-yl, l,2,3,4-tetrazol-5-yl, 5-oxazolyl, 1- pyrrolyl, 1-pyrazolyl, 1,2,3-triazol-l-yl, 1,2,4-triazol-l-yl, 1-tetrazolyl, 1-indolyl, 1- indazolyl, 2-isoindolyl, 7-oxo-2-isoindolyl,l-purinyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4, -oxadiazole, 4-oxo-2-thiazolinyl, or 5-methyl-l,3,4-thiadiazol-2-yl, thiazoledione, 1,2,3,4-thiatriazole, 1,2,4-dithiazolone. Each of these moieties may be substituted as appropriate. The term "halo" refers to fluoro, chloro, bromo, or iodo.
The compounds of the present invention can be converted to their salts, where appropriate, according to conventional methods.
The term "pharmaceutically acceptable salts" refers to acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form. When Q is the structure of
Figure imgf000027_0001
the dotted line in the heterocyclic ring means that this bond can be either single or double. In the case where the dotted line is a double bond, the R39 group will not be present. The compounds of formula I of this invention contain a chiral center at C5 of the isoxazoline ring, and as such there exist two enantiomers or a racemic mixture of both. This invention relates to both the enantiomers, as well as mixtures containing both the isomers. In addition, depending on substituents, additional chiral centers and other isomeric forms may be present in any of A or R-, group, and this invention embraces all possible stereoisomers and geometric forms in these groups. The compounds below are typical isoxazolines of this invention. It will be understood that the named compounds do not limit the scope of the invention, but are named merely to help one skilled in the art to understand the invention.
1. (±)-N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l-yl)phenyl]-5- isoxazolyljmethyljacetamide;
2. tert-Butyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3-isoxazolyl]phenyl]-3,6- dihydro-l(2H)-pyridinecarboxylate;
3. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-(4-methoxy-5-oxo- 1,3,6-cycloheptatrien- 1- yl)phenyl]-5-isoxazolyljmethyl]acetamide; 4. (±)-N-[[4,5-Dihydro-3-[3,5-difluoro-4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l- yl)phenyl]-5-isoxazolyl]methyl]acetamide;
5. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-4-piperidinyl]-3,5- difluorophenyl]-5-isoxazolyl]methyl]acetamide;
6. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4- yljphenylj-5-isoxazolyl]methyl]acetamide;
7. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4-yl]- 3-fluorophenyl]-5-isoxazolyl]methyl]acetamide;
8. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4-yl]- 3,5-difluorophenyl]-5-isoxazolyl]methyl]acetamide; 9. N-[[4,5-Dihydro-3-[4-(l,2,3,6-tetrahydropyridinyl)phenyl]-5-isoxazolyl]- methyljacetamide;
10. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3- fluorophenyl]-5-isoxazolyl]methyl]acetamide;
11. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3,5- difluorophenyl]-5-isoxazolyl]methyl]acetamide;
12. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinyl]phenyl]-5- isoxazolyl jmethyl jacetamide ;
13. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinyl]-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide; 14. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinyl]-3,5-difluorophenyl]- 5-isoxazolyl]methyl]acetamide;
15. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide;
16. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-pyran-4-yl)-3-fiuorophenyl]-5- isoxazolyljmethyljacetamide;
17. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-pyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyl]methyl]acetamide;
18. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide;
19. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide;
20. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyl]methyl]acetamide;
21. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide; 22. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide;
23. (±)-N-[t4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxaz olyl]methyl] acetamide;
24. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide;
25. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide;
26. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyl]methyl]acetamide; 27. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide S-oxide;
28. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide S-oxide;
29. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide S-oxide;
30. (±)-iV-t[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide S,S-dioxide;
31. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide S,S-dioxide; 32. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyl]methyl]acetamide S,S-dioxide;
33. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyl]methyl]acetamide S-oxide;
34. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyl]methyl]acetamide S-oxide;
35. (±)-N-[t4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide S-oxide;
36. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
37. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fiuorophenylj-5- isoxazolyljmethyljacetamide S,S-dioxide;
38. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
39. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[ l-(carboxymethyl)-3-(3- methyl)azetidinyl]phenylj-5-isoxazolyl]methyl]acetamide; 40. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[ l-(formyl)-3-(3-methyl)azetidinyl]phenyl]-5- isoxazolyljmethyljacetamide;
41. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(carboxymethyl)-3-azetidinyljphenylj-5- isoxazolyljmethyljacetamide;
42. (±)-iV-[[4,5-Dihydro-3-[3-fluoro-4-[l-(formyl)-3-azetidinyl]phenylj-5- isoxazolyljmethyljacetamide;
43. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(hydroxyacetyl)-3-pyrrolidinyl]phenylj-5- isoxazolyljmethyljacetamide;
44. (±)-iV-[[4,5-Dihydro-3-[3-fluoro-4-[l-(formyl)-3-pyrrolidinyl]phenylj-5- isoxazolyljmethyljacetamide; 45. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-yl]phenylj-5-isoxazolyl]methyl]acetamide;
46. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-yl]-3-fluorophenyl]-5-isoxazolyljmethyl]acetamide;
47. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-yl]-3,5-difluorophenyl]-5-isoxazolyljmethylJacetamide;
48. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4- piperidinyl]phenylJ-5-isoxazolyl]methyl]acetamide;
49. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4-piperidinyl]-3- fluorophenylj-5-isoxazolyljmethyljacetamide; 50. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4-piperidinyl]-3,5- difluorophenylJ-5-isoxazolyljmethyljacetamide;
51. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4- yljphenylj-5-isoxazolyljmethyljacetamide;
52. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4-ylj-3- fluorophenylJ-5-isoxazolyl]methyl]acetamide;
53. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4-yl]- 3,5-difluorophenylj-5-isoxazolyl]methyl]acetamide;
54. (±)-N-t[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-4-piperidinyl]phenyl]-5- isoxazolyljmethyljacetamide;
55. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-4-piperidinylj-3-fluorophenyl]- 5-isoxazolyl]methyl]acetamide;
56. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(hydroxyacetyl)-4-pyridinyl]phenylj- 5-isoxazolyl]methyl]acetamide;
57. (R)-N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(hydroxyacetyl)-4- pyridinyljphenyl]-5-isoxazolyl]methyl]acetamide; 58. Methyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3-isoxazo.yl]phenylj-3,6- dihydro-l(2H)-pyridinecarboxylate;
59. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(acetyl)-4-pyridinyl]phenyl]-5- isoxazolyljmethyljacetamide; or
60. (R)-N-[[4,5-Dihydro-3-[4-(4-pyridinyl)phenylJ-5-isoxazolyl]methyljacetamide.
The compounds of this invention can be prepared in accordance to one or more of the processes discussed below.
CHART I
A— CHO N— O" NO, 1
.OH
Figure imgf000032_0001
Figure imgf000032_0002
Figure imgf000032_0003
Figure imgf000032_0004
In CHART I, A and Rj are as defined previously. Aryl or heteroaryl aldehyde 1 can be converted to nitrile oxide 3 via three steps: formation of a corresponding oxime, halogenation of resultant oxime to generate an intermediate hydroximinoyl halide, and treatment of this intermediate with a suitable base such as triethylamine to afford nitrile oxide 3. Alternatively, nitrile oxide 3 can be prepared from a aryl or heteroaryl nitromethanes 2. The second method is preferred when functional groups are sensitive to the halogenation step of the first reaction. All these methods are well known to those skilled in the art, and are discussed in further detail in the following references: P. Caramella et al., "1,3-Dipolar Cycloaddition Chemistry", Vol. 1, Chapter 3 of "Nitrile Oxides and Imines", A. Padwa, Ed., John Wiley & Sons, Inc., New York, 1984, pp. 291-392, and references cited therein; C. J. Easton et al., "Advances in Heterocyclic Chemistry", Vol. 60 of "Cycloaddition Reactions of Nitrile Oxides with Alkenes", A. R. Katritzky, Ed., Academic Press, San Diego, 1994, pp. 261-327, and references cited therein; C. Grundmann, et al., J. Org. Chem. , 1968, Vol. 33, p. 476; K. C. Liu et al., J. Org. Chem. 1980, Vol. 45, p. 3916; T. Mukaiyama et al., J Am. Chem. Soc , 1960, Vol. 82, p. 5339. The resultant nitrile oxide 3 undergoes a 1,3-dipolar cycloaddition with a allyl alcohol to provide isoxazolines of structure 4. (See the references cited above). Compound 4 is then converted to the corresponding alkylsulfonate or arylsulfonate 5. A representative alkylsulfonyl derivative, the mesylate (R' = CH3), is prepared by reacting 4 with methanesulfonyl chloride/pyridine or methanesulfonyl chloride/triethylamine/dichloromethane. Utilization of arylsulfonyl chloride reagents, for example p-toluenesulfonyl chloride/pyridine or 3-nitrobenzenesulfonyl chloride/triethylamine/dichloromethane, affords aryl sulfonates such as the tosylate (R1 = p-tolyl) or nosylate (R1 = 3-nitrophenyl), respectively. The alkylsulfonate or arylsulfonate derivative 5 is then converted to the corresponding 5- (aminomethyl)isoxazoline 6 by treatment with aqueous ammonia in a suitable solvent system, for example acetonitrile/isopropanol or tetrahydrofuran/isopropanol, in a sealed reaction vessel, and at a temperature ranging from 40 to 90 °C. It will be apparent to those skilled in the art that alternative synthetic procedures for the introduction of the requisite aminomethyl side chain are available. For example, the sulfonate 5 can be reacted with an azide source such as sodium or potassium azide in an aprotic solvent such as N,iV-dimethylformamide or l-methyl-2-pyrrolidinone optionally in the presence of a catalyst such as 18-crown-6 at a temperature of 50 to 90 °C to generate the corresponding 5-(azidomethyl)isoxazoline. The azide moiety is then reduced by hydrogenation with a palladium or platinum catalyst in a suitable solvent such as ethyl acetate or methanol to give structure 6. Alternatively, the azidomethyl intermediate can be reduced to the corresponding amine 6 by a two-step process involving treatment with a trivalent phosphorus compound such as triphenylphosphine in a suitable solvent such as tetrahydrofuran followed by hydrolysis of the resultant iminophosphorane with water. See: M. Vaultier, et al., Tetrahedron Lett. 1983, Vol. 24, p. 763. The amine 6 is then acylated by reactions known to those skilled in the art to give isoxazolines of structure 7. For example, the amine 6 can be reacted with an acid chloride or anhydride in a basic solvent system such as pyridine at a temperature ranging from -30 to 30 °C to provide the acylated compound 7. Various methods for acylation reactions are discussed further in J. March, "Advanced Organic Chemistry", 3rd ed., John Wiley & Sons, Inc., New York, 1985, pp. 370-375.
CHART II depicts a method especially adapted to the preparation of the compounds of formula I wherein the A moiety is a phenyl ring with an appended moiety Q or substituted alkene.
CHART II
Figure imgf000035_0001
10
Figure imgf000035_0002
As shown in CHART II, benzaldehyde 8 or phenylnitromethane 9 is converted to compound 11 via the intermediate, nitrile oxide 10. In CHART II, D is bromo, iodo or triflate, the substituent a is R^g or R43 as defined previously, and the substituent b is hydrogen or R2 as defined previously. The process is conducted following the similar procedure described in CHART I. Compound 11 is then reacted with Rx-I (wherein I is an appropriate group such as SnMe3, SnBu3, B(OH)2, or ZnCl, and Rx is a Q moiety or a substituted alkene) in the presence of a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium dichloride, tris(dibenzylideneacetone)dipalladium and the like in a suitable solvent such as 1,4-dioxane or l-methyl-2-pyrrolidinone optionally in the presence of tri(2-furyl)phosphine, triphenylarsine, or tri(o-tolyl)phosphine and the like at a temperature in a range from about 70 °C to about 100 °C. The reaction affords the coupled product 12. This palladium- catalyzed coupling method is discussed in such references as J. K. Stille, Angew. Chem., Int. Ed. Engl., 1986, Vol. 25, p. 508; S. Hyuga et al., Chem. Letters, 1988, p. 809; M. Ogima, et al., Chem Letters, 1989, p. 1959; A. Suzuki, Pure Appl. Chem. 1991, Vol. 63, p. 419.
Alternatively, the compound 11 can be converted to the corresponding tin derivative (wherein D is tin radical such as SnMe3 or SnBu3) by procedures described in W. D. Wulff et al., J. Org. Chem., 1986, Vol. 51, p. 277. The resultant stannane is then coupled with Rx-I, following the similar palladium-catalyzed method, to provide 12. In this instance, the group I is bromo, iodo, or triflate.
A method for preparation of enantiomerically enriched isoxazolines of formula I can be prepared according to a procedure outlined in CHART III.
CHART III
Figure imgf000036_0001
As illustrated in CHART III, reaction of nitrile oxides 3 with α,β-unsaturated esters or amides 13 undergoes an asymmetric 1,3-dipolar cycloaddition to provide compound 14. In this reaction, group R" is a chiral auxiliary used to control the direction of asymmetric induction, and therefore it allows the asymmetric cycloaddition to occur with high steroselectivity. Compound 13 can be prepared from, among the others, Kemp's triacid, Oppolzer's sultam, or c/iiro-inositol as described in such references as D. P. Curran et al., J. Am. Chem. Soc, 1989, Vol. 111, p. 9238; J. A. Stack, et al, Tetrahedron, 1993, Vol. 49, p. 995; D. P. Curran et al., Tetrahedron Lett., 1988, Vol., 29, p. 3555; W. Oppolzer, et al., Tetrahedron Lett., 1991, Vol. 32, p. 4893; T. Akiyama et al., Tetrahedron Lett., 1992, Vol. 33, p. 5763; Y. H. Kim et al, Tetrahedron Lett, 1993, Vol. 34, p. 6063; C. J. Easton et al., "Advances in Heterocyclic Chemistry", Vol. 60 of "Cycloaddition Reactions of Nitrile Oxides with Alkenes", A. R. Katritzky, Ed., Academic Press, San Diego, 1994, pp.261-327, and references cited therein. Use of appropriate chiral auxiliaries to control the steroselectivity of the asymmetric 1,3-dipolar cycloaddition provides access, ultimately, to both enantiomers of 15. For simplicity, only one diastereomer of 14 is presented. The diastereomeric cycloadducts 14 may be further purified by recrystallization or chromatography. Treatment of the cycloadducts 14 with a suitable reducing agent such as L-selectride (commercially available) in an appropriate solvent such as tetrahydrofuran then provides the enantiomerically enriched 5-(hydroxymethyl)isoxazolines 15. Alternatively, compound 15 can be prepared by treatment of a nitrile oxide 3 with allyl alcohol in the presence of diethylzinc and a (R,R)- or (S,S)-tartaric acid ester, preferably, a diisopropyl ester, in a suitable solvent such as chloroform or dichloromethane and at a temperature in the range of about -20°C to about 0 °C. See Y. Ukaji et al., Chem. Letters, 1993, p. 1847. The remaining synthetic steps which lead to compound 16 are similar to the procedures outlined in CHART I.
In addition, racemic esters of structural formula 14 (wherein R" is OMe or OEt) can be resolved by an enzymatic ester hydrolysis procedure described in S. Yang et al., Monatsh. Chem., 1994, Vol, 125, p. 469. Racemic isoxazoline intermediates of structure 11 have also been separated into the individual (R)- and (S)-enantiomers by column chromatography, employing a Chiralpak AD column, and eluting with isopropanol hexane mixtures as the mobile phase.
As described above, the preparation of the compounds of the invention starts with an appropriately substituted aryl or heteroaryl aldehyde, or with an appropriately substituted aryl or heteroaryl nitromethane. In many instances, the starting aldehydes or nitromethane derivatives are available commercially from chemical firms such as, for example, Aldrich Chemical Company, Inc., Milwaukee, WS; TCT America, Portland, OR; Lancaster Synthesis, Windham, NH; Maybridge Chemical Co. Ltd., Cornwall, UK - North American agent; Ryan Scientific, Columbia, SC; Fluka Chemika, Ronkonkoma, NY; Pfaltz & Bauer, Waterbury, CT; and Eastman Organic Chemicals, Eastman Kodak Company, Rochester, NY. In any event, all of the starting aldehydes and nitromethane derivatives can be prepared readily by one having ordinary skill in the organic chemistry art utilizing well known procedures. For example, about 40 preparative methods are summarized in R.B. Wagner et al., "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York, 1953, Chapter 9, pp. 279-315. Furthermore, various methods are discussed in references such as, for example, S. R. Sandier et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983, Vol. 1, Chapter 7; H. M. Colquhoun et al., "Carbonylation, Direct Synthesis of Carbonyl Compounds", Plenum Press, New York, 1991, Chapter 4; Patai, S., Ed., "The Chemistry of the Carbonyl Group", Interscience Publishers, John Wiley & Sons, Inc., New York, 1966, Chapters 2-7; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, CA, 1972; and H. O. Larson, "Methods of Formation of the Nitro Group in Aliphatic and Alicyclic Systems", Part 1, Chapter of "The Chemistry of the Nitro and Nitroso Groups", Feuer, H., Ed., Interscience Publishers, John Wiley & Sons, Inc., New York, 1969. The pharmaceutical compositions of this invention may be prepared by combining the compounds of formula I of this invention with a solid or liquid pharmaceutically acceptable carrier, and optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water, water-propylene glycol, and water-polyethylene glycol systems, optionally containing conventional coloring agents, flavoring agents, stabilizers and thickening agents. The pharmaceutical composition is provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula I according to this invention.
The quantity of active component, that is, the compounds of formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
In therapeutic use for treating bacterial infections in humans and other animals that have been diagnosed with bacterial infections, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 100 mg/kg, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compounds being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood- level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day. These compounds are useful for the treatment of microbial infections in humans and other warm blooded animals by either parenteral, oral, or topical administration. In general, the preferred form of administration is orally. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compounds according to formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a suitably buffered isotonic solution having a pH of about 3.5 - 6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine, to name a few. The compounds according to formula I generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml. The resulting liquid pharmaceutical composition will be administered so as to obtain the above mentioned antibacterially effective amount of dosage. The compounds of formula I according to this invention are advantageously administered orally in solid and liquid dosage forms.
The compounds of this invention are useful antimicrobial agents, effective against various human and veterinary pathogens, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-resistant organisms such as Mycobacterium tuberculosis and Mycobacterium avium. Humans or animals infected with such pathogens are readily diagnosed by a physician or veterinarian of ordinary skill. Antimicrobial activity was tested in vitro using the procedure described in National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically are disclosed in the third edition of Approved Standard, NCCLS Document M7-A3, Villanova, PA, 1993. Minimum inhibitory concentration (MIC) values were determined by an agar dilution method (1) in which the test medium was Mueller Hinton agar (MHA; Difco Laboratories, Detroit, MI) supplemented with 1% Supplement C (Difco). Serial twofold dilutions of each compound were prepared using 1.0 ml volumes of sterile distilled water. To each 1.0 ml aliquot was added 9.0 ml of molten agar medium. The drug-supplemented agar was mixed, poured into 15x100 mm petri dishes, and allowed to solidify and dry at room temperature prior to inoculation. The test cultures were grown aerobically overnight at 35 °C on MHA; streptococcal strains were grown on Trypticase Soy Blood Agar Base EH (Difco) supplemented with 5% defibrinated sheep blood (BBL, Becton Dickinson Company, Cockeysville, MD). Colonies were harvested with a sterile swab, and cell suspensions were prepared in Trypticase Soy Broth (TSB; Becton Dickinson Company) to equal the turbidity of a 0.5 McFarland standard. A 1:19 dilution of the suspension was made in TSB; this diluted suspension constituted the inoculum for the assay. The plates containing the drug-supplemented agar were inoculated with a 0.001 ml drop of the cell suspensions using a Steers replicator (Melrose Machine Shop, Woodlyn, PA), yielding approximately 10 -10 cells per spot. The plates were incubated aerobically at 35°C for 18 hours and the MIC was read as the lowest concentration of drug that inhibited visible growth of the organism. The growth of a single colony was considered to be negative. The data are shown in TABLE 1.
TABLE 1
In Vitro Activity of Compounds Against Staphylococcus aureus UC No. 9213,
Enterococcus faecalis UC No. 9217 and Streptococcus Pneumoniae UC No. 9912.
Figure imgf000041_0001
Antimicrobial activity was also tested in vivo using the Murine Assay procedure. Groups of female mice (six mice weighing 18-20 grams each) were injected intraperitoneally with bacteria which were thawed just prior to use and suspended in brain heart infusion with 4% brewers yeast (Staphylococcus aureus). Antibiotic treatment at six dose levels per drug was administered one hour and five hours after infection by either oral intubation or subcutaneous routes. Survival was observed daily for six days. ED50 values based on mortality ratios were calculated using probit analysis. The subject compounds were compared against well known antimicrobial U- 100592 as controls. U- 100592 has been extensively evaluated in this animal model versus vancomycin, and has routinely been shown to be equipotent to vancomycin. See: Antimicrob. Agents Chemother., Vol. 40, No. 6, 1996, pp. 1508-1513; Antimicrob. Agents Chemother., Vol. 40, No. 4, 1996, pp. 839-845; and Upjohn Oxazolidinone Antibacterial Agents, Posters Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 17-20 September 1995. The data are shown in TABLE 2.
TABLE 2
In Vivo Activity of Compounds Against S, aureus UC No. 9213
Figure imgf000041_0002
The compounds, processes and uses of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Both below and throughout the specification, it is intended that citations to the literature are expressly incorporated by reference herein.
EXAMPLE 1 Preparation of N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6- cycloheptatrien-l-yl)phenyl]-5-isoxazolyl]methyl]acetamide.
Figure imgf000042_0001
Step 1 Preparation of 4,5-Dihydro[3-(4-bromophenyl)-5-
(hydroxymethyl)jisoxazole.
To a flask containing 4-bromo-N-hydroxy-benzenecarboxiπύdoyl chloride (610 mg, 2.60 mmol) and allyl alcohol (0.14 mL, 2.08 mmol) in methylene chloride (30 mL) at 0 °C under an inert atmosphere is added triethylamine (0.36 mL, 2.60 mmol). The reaction is slowly warmed to ambient temperature, stirred 20 hours, quenched with water (30 mL), and extracted with methylene chloride (2 X 50 mL). The organic extracts are combined, washed with saline (50 mL), dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 200 mL), eluting with chloroform/methanol (99/1). The appropriate fractions are combined (Rf- 0.06, TLC, hexane/ethyl acetate, 75/25) and concentrated in vacuo to give the title compound, mp 104-105 °C.
Step 2 Preparation of N-[[4,5-Dihydro-3-[4-bromophenyl]-5- isoxazolyljmethyljacetam.de.
To a flame dried flask containing 4,5-dihydro[3-(4-bromophenyl)-5- (hydroxymethyl)jisoxazole (520 mg, 2.03 mmol) in methylene chloride (20 mL) at 0 °C under an inert atmosphere is added triethylamine (0.43 mL, 3.05 mmol) and methanesulfonyl chloride (0.21 mL, 2.13 mmol). The reaction is slowly warmed to ambient temperature, stirred 3 hours, and quenched with water (25 mL). The organic phase is separated, washed with saturated NaHC03 (25 mL) and saline (25 mL), dried over sodium sulfate and concentrated in vacuo to give crude 4,5- dihydro[3-(4-bromophenyl)- 5-[[(methylsulfonyl)oxyjmethyl]Jisoxazole. The crude 4,5- dihydro[3-(4-bromophenyl)- 5-[[(methylsulfonyl)oxyjmethylj]isoxazole (680 mg, 2.03 mmol) is dissolved in tetrahydrofuran (4 mL), isopropanol (4 mL), and concentrated ammonium hydroxide (4 mL) in a thick wall resealable vessel and heated to 100-110 °C for 15 hours. The reaction is cooled to ambient temperature, diluted with ethyl acetate (50 mL), washed with saline (20 mL), dried over sodium sulfate and concentrated in vacuo to give crude 4,5-dihydro[3-(4-bromophenyl)-5-(aminomethyl)j- isoxazole. The crude 4,5-dihydro[3-(4-bromophenyl)-5-(aminomethyl)jisoxazole (520 mg, 2.03 mmol) is dissolved in methylene chloride (15 mL) and cooled to 0 °C under an inert atmosphere. Pyridine (0.51 mL, 6.09 mmol) and acetic anhydride (0.24 mL, 2.54 mmol) are added to the cooled solution and stirred 20 hours at ambient temperature. The reaction is concentrated in vacuo, diluted with methylene chloride (50 mL), washed with saline (25 mL), dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 200 mL), eluting with chloroform/methanol (98/2). The appropriate fractions are combined (R^= 0.13, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, mp 198-199 °C.
Step 3 Preparation of N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6- cycloheptatrien-l-yl)phenyl]-5-isoxazolyljmethyl]acetamide.
To a flame dried flask containing a pre-stirred slurry of l-methyl-2- pyrrolidinone (5 mL), tris(dibenzylideneacetone)dipalladium (60 mg, 0.07 mmol), tri(2-furyl)phosphine (30 mg, 0.13 mmol) under an inert atmosphere is added N- [[4,5-dihydro-3-[4-bromophenyl]-5-isoxazolyl]methyl]acetamide (193 mg, 0.65 mmol) and 2-methoxy-5-trimethylstannyltropone in l-methyl-2-pyrrolidinone (5 mL) and heated to 90 °C for 12 hours. The reaction is diluted with ethyl acetate (100 mL) and water (50 mL). The organic phase is separated and the aqueous phase is extracted with methylene chloride (4X50 mL). The organic extracts are combined, dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (98/2). The appropriate fractions are combined ( j= 0.10, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, mp >230 °C. The compound of Example 1, Step 1, can be prepared enantiomerically pure by a procedure from Ukaji, Y.; Sada, K.; Inomata, K. Chem. Lett. 1993, pp 1847-1580.
EXAMPLE 2 Preparation of tert-Butyl 4-[4-[5-[(acetylamino)methylj-4,5-dihydro-3- isoxazolyljphenylj-3,6-dihydro-l(2H)-pyridinecarboxylate.
Figure imgf000044_0001
Step 1 Preparation of N-[[4,5-Dihydro-3-[4-(trimethylstannyl)phenyl]-5- isoxazolyljmethylj-acetamide. To a flame dried flask containing 1,4-dioxane (10 mL), dichlorobis-
(triphenylphosphine)palladium (II) (60 mg, 0.08 mmol) and N-[[4,5-dihydro-3-[4- bromophenylj-5-isoxazolyljmethyljacetamide (450 mg, 1.52 mmol) under an inert atmosphere is added hexamethylditin (550 mg, 1.68 mmol) and heated to 100 °C for 12 hours. The reaction is concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 200 mL), eluting with chloroform/acetonitrile (94/6). The appropriate fractions are combined (Rf= 0.34, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, NMR (CDCL3, 400 MHz) 7.58, 7.52, 6.22, 4.85, 3.59, 3.51, 3.39, 3.12, 1.98, 0.30. Step 2 Preparation of 3,6-Dihydro-4-[[(trifluoromethyl)sulfonyljoxy]-l(2H)- pyridinecarboxylic acid 1,1-dimethylethyl ester.
A solution of freshly distilled diisopropylamine (8.70 mL) in dry tetrahydrofuran (133 mL) at -78 °C under N2 is treated with n-butyllithium (1.6M in hexanes, 41.5 mL) dropwise over 10 minutes, and the resulting mixture is stirred at -78 °C for 1 hour and is then treated with a solution of 1-(1,1- dimethylethoxycarbonyl)-4-piperidone (12.0 g) in dry tetrahydrofuran (120 mL) dropwise over 10 minutes. The resulting mixture is stirred at -78 °C for 40 minutes and is then treated with a solution of N-phenyltrifluoromethanesulfonimide (22.0 g) in dry tetrahydrofuran (62 mL) over 5 minutes. The reaction mixture is stirred at - 78 °C for 10 minutes and at 0 °C for 4 hours and is then quenched with water (200 mL). The layers are separated, the aqueous phase is extracted with diethyl ether (100 mL) and the combined organic phase is washed with saline (50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound, NMR (CDC13, 400 MHz) 5.77, 4.05, 3.64, 2.45, 1.48. Step 3 Preparation of tert-Butyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3- isoxazolyl]phenylj-3,6-dihydro-l(2H)-pyridinecarboxylate.
To a flame dried flask containing a pre-stirred slurry of l-methyl-2- pyrrolidinone (15 mL), tris(dibenzylideneacetone)dipalladium (30 mg, 0.03 mmol), triphenylarsine (4 mg, 0.12 mmol) under an inert atmosphere is added N-[[4,5- dihydro-3-[4-(trimethylstannyl)phenyl]-5-isoxazolyl]methyljacetamide (580 mg, 1.52 mmol) and 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxyj-l(2H)-pyridinecarboxylic acid 1,1-dimethylethyl ester (450 mg, 1.37 mmol) and stirred for 12 hours. The reaction is diluted with ethyl acetate (100 mL) and water (50 mL). The organic phase is separated, extracted with water (5 X 50 mL), dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with methylene chloride/methanol (99/1). The appropriate fractions are combined (Rf= 0.28, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, mp 117-120 °C.
EXAMPLE 3 Preparation of N-[[4,5-Dihydro-3-[4-(l,2,3,6-tetrahydropyridinyl) phenyl]-5-isoxazolyl]methylJacetarnide.
Figure imgf000045_0001
To a flame dried flask containing terf-Butyl 4-[4-[5-[(acetylamino)methyl]-4,5- dihydro-3-isoxazolyljphenyl]-3,6-dihydro-l(2H)-pyridinecarboxylate (270 mg, 0.68 mmol) in methylene chloride (15 mL) at 0°C is added trifluoroacetic acid (1.04 mL, 13.52 mmol). The reaction is stirred 1 hour at 0 °C and 2 hours at ambient temperature. The reaction is poured over a slurry of ice in saturated potassium carbonate (15 mL). The resulting aqueous phase is extracted with methylene chloride (5 X 25 mL). The extracts are dried over sodium sulfate concentrated in vacuo to give the title compound, MS (ESI+) for C17H21N302 m/z 300.2 (M+H)+.
EXAMPLE 4 Preparation of N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l- (hydroxyacetyl)-4-pyridinyl]phenylj-5-isoxazolyl]methyljacetamide.
Figure imgf000046_0001
To a flask containing N-[[4,5-dihydro-3-[4-[ 1,2,3, 6-tetrahydropyridinylJ- phenyl]-5-isoxazolyl]methyl]acetamide (185 mg, 0.62 mmol) in methylene chloride (20 mL) and triethylamine (0.17 mL, 1.24 mmol) is added acetoxyacetyl chloride (0.09 mL, 0.81 mmol) at 0 °C under an inert atmosphere. The reaction is warmed to ambient temperature, stirred for 2 hours and concentrated in vacuo. The residue is dissolved in methanol (15 mL) and potassium carbonate (260 mg, 1.88 mmol) is added. The reaction is stirred fifteen hours, concentrated in vacuo, and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (98/2). The appropriate fractions are combined
Figure imgf000046_0002
0.10, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, mp 115-118 °C.
EXAMPLE 5 Preparation of (R)-N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l- (hydroxyacetyl)-4-pyridinyl]phenyl]-5-isoxazolyl]methyl]acetamide.
Figure imgf000046_0003
Following the general procedure of EXAMPLE 4 and making noncritical variations but substituting (R)-N-[[4,5-dihydro-3-[4-[l,2,3,6-tetrahydropyridinyl]- phenyl]-5-isoxazolyl]methyl]acetamide (280 mg, 0.94 mmol) for N-[[4,5-dihydro-3-[4- [l,2,3,6-tetrahydropyridinyl]phenyl]-5-isoxazolyl]methyl]acetamide the title compound is obtained, HRMS calcd for C19H23N304: 357.1689. Found: 357.1694.
EXAMPLE 6 Preparation of Methyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3- isoxazolyl]phenylj-3,6-dihydro-l(2H)-pyridinecarboxylate.
Figure imgf000047_0001
To a flask containing N-[[4,5-dihydro-3-[4-[l,2,3,6-tetrahydropyridinyl]-phe- nyl]-5-isoxazolyl]methyl]acetamide (300 mg, 1.00 mmol) in acetone (7 mL), water (7 mL) and potassium carbonate (207 mg, 1.50 mmol) is added methylchloroformate (0.09 mL, 1.10 mmol) at 0 °C under an inert atmosphere. The reaction is warmed to ambient temperature stirred fifteen hours, concentrated in vacuo, and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (98/2). The appropriate fractions are combined (Rf= 0.14, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, HRMS calcd for C19H23N304: 357.1689. Found: 357.1666.
EXAMPLE 7 Preparation of N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(acetyl)-4- pyridinyl]phenyl]-5-isoxazolyljmethyl]acetamide.
Figure imgf000047_0002
To a flask containing N-[[4,5-dihydro-3-[4-[l,2,3,6-tetrahydropyridinyl]-phe- nyl]-5-isoxazolyl]methyl]acetamide (300 mg, 1.00 mmol) in methylene chloride (15 mL) and triethylamine (0.28 mL, 2.00 mmol) is added acetyl chloride (0.08 mL, 1.10 mmol) at 0 °C under an inert atmosphere. The reaction is warmed to ambient temperature stirred fifteen hours, concentrated in vacuo, and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (98/2). The appropriate fractions are combined 0.18, TLC, chloroform/methanol, 95/5) and concen- trated in vacuo to give the title compound, HRMS calcd for C^^gNgOjj.- 341.1739. Found: 341.7125. EXAMPLE 8 Preparation of (R)-N-[[4,5-Dihydro-3-[4-(4-pyridinyl)phenyl]-5- isoxazolyljmethyljacetam.de.
Figure imgf000048_0001
Step 1 Preparation of 4-(Trimethylstannyl)pyridine.
To a flame dried flask containing 4-bromopyridine (950 mg, 6.01 mmol), 1,4- dioxane (60 mL) is added hexamethylditin (2.07 g, 6.31 mmol) and dichlorobis- (triphenylphosphine)palladium(II) (110 mg, 0.15 mmol) and heated to 100 °C for 22 hours. The reaction is concentrated in vacuo, and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform (100) then chloroform/acetonitrile (90/10). The appropriate fractions are combined (R^= 0.24, TLC, chloroform/acetonitrile, 90/10) and concentrated in vacuo to give the title compound, MS (ESI+) for C8H13NSn m/z 244.2 (M+H)+. Step 2 Preparation of (R)-4,5-Dihydro[3-[4-(4-pyridinyl)phenyl-5-
(hydroxymethyl)]]isoxazole.
To a flame dried flask containing a pre-stirred slurry of l-methyl-2- pyrrolidinone (8 mL), tris(dibenzylideneacetone)dipalladium (490 mg, 0.54 mmol), tri(2-furyl)phosphine (250 mg, 1.07 mmol) under an inert atmosphere is added (R)- 4,5-dihydro[3-(4-bromophenyl)-5-(hydroxymethyl)]isoxazole (1.38 g, 5.37 mmol) and 4-(Trimethylstannyl)pyridine in l-methyl-2-pyrrolidinone (5 mL) and heated to 90 °C for 12 hours. The reaction is diluted with ethyl acetate (100 mL) and water (50 mL). The organic phase is separated and the aqueous phase is extracted with methylene chloride (4X50 mL). The organic extracts are combined, dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 100 mL), eluting with chloroform/methanol (99/1). The appropriate fractions are combined (Rf= 0.25, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, MS (ESI+) for C15H14N202 m/z 255.1 (M+H)+. Step 3 Preparation of (R)-N-[[4,5-Dihydro-3-[4-(4-pyridinyl)phenyl]-5- isoxazolyljmethyljacetamide.
To a flame dried flask containing (R)-4,5-Dihydro[3-[4-(4-pyridinyl)phenyl]-5- (hydroxymethyl)jisoxazole (440 mg, 1.73 mmol) in methylene chloride (20 mL) at 0 °C under an inert atmosphere is added triethylamine (0.36 mL, 2.60 mmol) and methanesulfonyl chloride (0.14 mL, 1.82 mmol). The reaction is slowly warmed to ambient temperature, stirred 3 hours, and quenched with water (25 mL). The or- ganic phase is separated, washed with saturated NaHC03 (25 mL) and saline (25 mL), dried over sodium sulfate and concentrated in vacuo to give crude (R)-4,5- dihydro[3-[4-(4-pyridinyl)phenyl]-5-[[(methylsulfonyl)oxy]methyljisoxazole. The crude (R)-4,5-dihydro[3-[4-(4-pyridinyl)phenylj-5-[[(methylsulfonyl)oxyj- methyljisoxazole (580 mg, 1.73 mmol) is dissolved in tetrahydrofuran (4 mL), isopropanol (4 mL), and concentrated ammonium hydroxide (4 mL) in a thick wall resealable vessel and heated to 100-110 °C for 15 hours. The reaction is cooled to ambient temperature, diluted with ethyl acetate (50 mL), washed with saline (20 mL), dried over sodium sulfate and concentrated in vacuo to give crude (R)-4,5- dihydro[3-[4-(4-pyridinyl)phenyl]-5- (aminomethyl)isoxazole. The crude (R)-4,5- dihydro[3-[4-(4-pyridinyl)phenyl]-5- (aminomethyl)isoxazole (320 mg, 1.57 mmol) is dissolved in methylene chloride (15 mL) and cooled to 0 °C under an inert atmosphere. Pyridine (0.31 mL, 3.78 mmol) and acetic anhydride (0.15 mL, 1.57 mmol) are added to the cooled solution and stirred 20 hours at ambient temperature. The reaction is concentrated in vacuo, diluted with methylene chloride (50 mL), washed with saline (25 mL), dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (230-400 mesh, 200 mL), eluting with chloroform/methanol (97/3). The appropriate fractions are combined (Rr= 0.14, TLC, chloroform/methanol, 95/5) and concentrated in vacuo to give the title compound, mp 244-245 °C.

Claims

CLAIMS We claim: 1. A compound of the formula I
Figure imgf000050_0001
I or pharmaceutical acceptable salts thereof wherein: Rj is a) H, b) Cj_8 alkyl optionally substituted with one or more F, CI, OH, Cj.4 alkoxy, or acyloxy, c) C3.g cycloalkyl, or d) C 8 alkoxy; A is
Figure imgf000050_0002
Figure imgf000050_0003
Figure imgf000050_0004
d) a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom, wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R 8, e) a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three Rgg, f) a β-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three R55,
Figure imgf000051_0001
Figure imgf000051_0002
a) -S(=O)i R4, b) -S(=0)2-N=S(0)jR5R6,
Figure imgf000052_0001
a) C1 4 alkyl optionally substituted with one or more halos, OH, CN, NR10Rπ, or -C02R13, b) C2 4 alkenyl, c) -NR16R18, d) -N3, e) -NHC(=0)R7, f) -NR2fJC(=0)R7, g) -N(R19 ) 2- h) -NR16R19, or i) -NR19R20;
Rg and Rg at each occurrence are the same or different and are a) C1 2 alkyl, or b) Rg and Rg taken together are -(CH2)jc-; R7 is C1-4 alkyl optionally substituted with one or more halos; R8 is a) H, or b) Cj__g alkyl optionally substituted with one or more halos, or C3.8 cycloalkyl; R9 is C1 4 alkyl substituted with one or more
Figure imgf000053_0001
c) I; Rgg is a physiologically acceptable cation; Rgj and R22 at each occurrence are the same or different and are a) H, b) Cj.4 alkyl, or c) -NR22R22 taken together are -(CH2)m-; wherein R23 and R24 at each occurrence are the same or different and are a) H, b) F,
Figure imgf000054_0003
Q is a) -
Figure imgf000054_0001
c) '^X
d)
Figure imgf000054_0002
Figure imgf000055_0001
0 ^ N s
Figure imgf000055_0002
Figure imgf000055_0003
Figure imgf000055_0004
j) OT 1*
Figure imgf000055_0005
Figure imgf000055_0006
m) a diazinyl group optionally substituted with X and Y, n) a triazinyl group optionally substituted with X and Y, o) a quinolinyl group optionally substituted with X and Y, p) a quinoxalinyl group optionally substituted with X and Y, or q) a naphthyridinyl group optionally substituted with X and Y;
B is an unsaturated 4-atom linker having one nitrogen and three carbons;
M is
is
W is
X is
Figure imgf000056_0001
i) -S(=0)2-N=S(0)jR5Rg, j) -SC(=0)R7,
Figure imgf000057_0001
1) -C(=0)NR27R28, m) -C(=NR29)R25.
Figure imgf000057_0002
o) -C(R25)(R28)-OC(=0)R13, p) -C(R28)(OR13)-(CH2)h-NR27R28, q) -NR27R28, r) -N(R27)C(=0)R7,
Figure imgf000057_0003
u) -C(R25)(R1g)-NR27R2g, or v) C-j__g alkyl substituted with one or more halos, OH, =0 other than at alpha position, -S(=0)jR17, -N 27 2g> C2.g alkenyl, C2.5 alkynyl, or C3.8 cycloalkyl; R4, Rg, Rg, R7, R13, R14, R15, R16, and R17 are the same as defined above; R25 is a) H, b) C^g alkyl optionally substituted with one or more halos, C3. cycloalkyl, C1 4 alkyl substituted with one or more of -S(=0)jR17,
-0R13, or 0C(=0)R13, NR27R28, or c) C2.g alkenyl optionally substituted with CHO, or C02R13; R26 is a) R28, or b) NR27N28;
R27 and R28 at each occurrence are the same or different and are a) H, b) Cj.8 alkyl, c) Cg g cycloalkyl, d) -(CH2)m0R13,
Figure imgf000057_0004
f) R27 and R28 taken together are -(CH2)20(CH2)2-, -(CH2)hCH(C0R7)-, or -(CH2)2N(CH2)2(R7);
R29 is a) -NR27R28, b) -0^27 or c) -NHC(=0)R28; wherein R30 is a) H, b) C _g alkyl optionally substituted with one or more halos, or c) C1 8 alkyl optionally substituted with one or more OH, or C^g alkoxy; wherein E is a) NR39, b) -S(=0)j, or c) O; R38 is a) H, b) C^g alkyl, c) -(CH2)q-aryl, or d) halo; R39 is a) H, b) C1_6 alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CH2)q-aryl, d) -CO2R40, e) -COR41, f) -C(=O)-(CH2)q-C(=O)R40, g) -S(=0)2-C1.6 alkyl, h) -S(=0)2-(CH2)q-aryl, or i) -(C=0)j-Het;
R40 is a) H, b) Cj. alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CH2)q-aryl, or d) -(CH2)q-OR42; R 41 is a) C-^g alkyl optionally substituted with one or more OH, halo, or -CN, b) -(CH2)q-aryl, or c) -(CH2)q-OR43;
R42 is a) H, b) .g alkyl, c) -(CH2)q-aryl, or d) -C(=0)-C1.6 alkyl; aryl is a) phenyl, b) pyridyl, or c) napthyl; wherein sections a to c can be optionally substituted with one or more halo, -CN, OH, SH, C-^g alkyl, C1 6 alkoxy, or C^g alkylthio; wherein R43 is a) H, b) Cχ_2 alkyl, c) F, or d) OH;
R44 s a) H, b) CF3, c)
Figure imgf000059_0001
alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) R44 and R4g taken together are a 5-, 6-, or 7-membered ring of the formula,
Figure imgf000059_0002
or f) R44 and R45 taken together are -(0^)^-, when R4 is an electron- withdrawing group;
R4g and R46 at each occurrence are the same or different and are a) an electron-withdrawing group, b) H, c) CFg, dd)) C 3 alkyl optionally substituted with one halo, e) phenyl, provided at least one of R45 or R46 is an electron-withdrawing group, or f) R45 and R46 taken together are a 5-, 6-, 7-membered ring of the formula
Figure imgf000060_0001
U is a) CH2, b) O, c) S, or d) NR47;
R47 is a) H, or b) C^g alkyl; wherein R48 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) -N02, h) C1 6 alkoxy, i) C^ alkoxycarbonyl, j) Cj.g alkythio, k) Cj.g acyl,
1) -NR49 R50, m) Cj. alkyl optionally substituted with OH, C1 5 alkoxy, Cj_g acyl, or -NR49R50, n) C2.8 alkenylphenyl optionally substituted with one or two Rgl, 0) phenyl optionally substituted with one or two R51, p) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two Rg^, or
Figure imgf000061_0001
R49 and R50 at each occurrence are the same or different and are a) H, b) Cχ_4 alkyl, c) Cg.g cycloalkyl, or d) R49 and R5Q taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, C^g alkyl, or C-^g acyl;
Figure imgf000061_0002
R54 is a) Cj.4 alkyl, or b) phenyl optionally substituted with C1 4 alkyl; wherein R55 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) -N02, h) C1 6 alkoxy, i) Cχ_g alkoxycarbonyl, j) C1_6 alkythio, k) Cj. acyl,
1) -NR56 R57, m) Cj alkyl optionally substituted with OH, Cχ g alkoxy, Cχ 5 acyl, or
-NR5gR57, n) C2_8 alkenylphenyl optionally substituted with one or two Rg8, o) phenyl optionally substituted with one or two R58, p) a 5- or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R58, or
Figure imgf000062_0001
Rgg and R57 at each occurrence are the same or different and are a) H, b) formyl, c) Cj^ alkyl, d) Cj^.4 acyl, e) phenyl, f) C3.g cycloalkyl, or g) Rg and Rg7 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C1 3 alkyl, or C^g acyl;
Figure imgf000063_0003
Figure imgf000063_0001
acyl, -NRggRgg, -SR67, -0-S02R68, or
R69— ( ^-NH-CO-O-
n) -C(=0)NR59 R60,
Figure imgf000063_0002
q) -SO2-NR59R60, r) -S(=0)iR54, s) -CH=N-R61, or t) -CH(0H)-S03R64;
R54 is the same as defined above; Rg9 and R6Q at each occurrence are the same or different and are a) H,
Figure imgf000063_0004
b) benzyloxy, c) -NH-C(=0)-NH2, d) -NH-C(=S)-NH2, or e) -NH-C(=NH)-NR62R63; R62 and Rg3 at each occurrence are the same or different and are a) H, or b) C1 4 alkyl optionally substituted with phenyl or pyridyl; R64 is a) H, or b) a sodium ion;
R6g and R66 at each occurrence are the same or different and are a) H, b) formyl, c) C 4 alkyl, d) C^ acyl, e) phenyl, f) C3,6 cycloalkyl, g) Rgg and Rgg taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C^g alkyl, or C1 3 acyl, h) -P(O)(OR70)(OR71), or
Figure imgf000064_0001
R67 is
Figure imgf000064_0002
α N -,
>- or I
I CH, CH,
R68 is Cl-3 alky^ R69 is a) C-j_.g alkoxycarbonyl, or b) carboxyl;
R7Q and R7 χ at each occurrence are the same or different and are
h occurrence are the same or different and are
Figure imgf000065_0001
substituted with OH, C1_5 alkoxy, C1 5 acyl, -NR78R79, -N(phenyl)(CH2-CH2-0H), -0-CH(CH3)(OCH2CH3), or -0-phenyl-[para- NHC(=0)CH3J,
0) C2_g alkenylphenyl optionally substituted with R j, p) phenyl optionally substituted with R51, or q) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, optionally substituted with R51; R51 is the same as defined above;
R7g and R79 at each occurrence are the same or different and are a) H, b) Ci.4 alkyl, c) phenyl, or d) R78 and R79 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, Cχ 3 alkyl, or C1 3 acyl; wherein T is a) 0, b) S, or c) S02;
R7g, R7g, and R77 are the same as defined above; R80 is a) H, b) formyl, c) carboxyl, d) C1 6 alkoxycarbonyl, e) Cj.g alkyl, f) C2_8 alkenyl, wherein the substituents (e) and (f) can be optionally substituted with OH, halo, Cj alkoxy, C-^ g acyl, Cχ alkylthio or C^g alkoxycarbonyl, or phenyl optionally substituted with halo, g) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, C1 6 alkyl, C1_6 alkoxy, C^ acyl, Cj.g alkylthio, or Cχ alkoxycarbonyl; h) -NR81R82> i) -OR90, j) -S(=0)fR91, k) -S02-N(R92)(R93), or
1) a radical of the following formulas:
Figure imgf000067_0001
R83R84 -^N- >
Figure imgf000067_0002
R81 and R at each occurrence are the same or different and are a) H, b) C3.6 cycloalkyl, c) phenyl, d) Cj.g acyl, e) C1 8 alkyl optionally substituted with OH, C1 6 alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, phenyl optionally substituted with OH, CF3, halo, -N02, C1 4 alkoxy, -NR83R84, or
£&
0 Sf— Rβ5 - or
R86— CH—
Figure imgf000067_0003
V is a) O, b) CH2, or
Figure imgf000068_0001
a) H, or b) C1 7 alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=0)-NH2,
-C02H, or -C(=NH)-NH2;
R87 IS a) H, b) phenyl, or c) Cj 6 alkyl optionally substituted by OH;
R88 and R 9 at each occurrence are the same or different and are
Figure imgf000068_0002
a) Cj 8 alkyl optionally substituted with C1 6 alkoxy or C1_g hydroxy, C3_g cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -N02, CFg, halo, -CN, OH, C-^g alkyl, C1 5 alkoxy, or Cj__5 acyl;
b) v' N-(CH2) - \ /
c) phenyl, or d) pyridyl; R91 is a) C1.16 alkyl, b) C2_16 alkenyl, wherein the substituents (a) and (b) can be optionally substituted with C1 6 alkoxycarbonyl, or a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, c) an aromatic moiety having 6 to 10 carbon atoms, or d) a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, C1 6 alkyl, Cj. alkoxy, Cj.g acyl, C1_6 alkylthio, or C1_6 alkoxycarbonyl; R92 and R93 at each occurrence are the same or different and are a) H, b) phenyl, c) C1.6 alkyl, or d) benzyl; R94 and R95 at each occurrence are the same or different and are a) H, b) OH, c) Cj 6 alkyl optionally substituted with -NRg3 R84, or d) R94 and R95 taken together are =0; R96 is a) an aromatic moiety having 6 to 10 carbon atoms, b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and 0, wherein the substituents (a) and (b) which can in turn be substituted with one or three -N02, CF3, halo, -CN, OH, phenyl, C1 5 alkyl, C^g alkoxy, or C1 5 acyl, c) morpholinyl, d) OH, e) C1 6 alkoxy, f) -NR83R84, g) -C(=0)-R97, or
Figure imgf000069_0001
Rg7 is a) morpholinyl, b) OH, or c) Cj.g alkoxy; h is 1, 2, or 3; i is 0, 1, or 2; j is 0 or 1; k is 3, 4, or 5; 1 is 2 or 3; m is 4 or 5; n is 0, 1, 2, 3, 4, or 5; p is 0, 1, 2, 3, 4, or 5; with the proviso that n and p together are 1, 2, 3, 4, or 5; q is 1, 2, 3, or 4; r is 2, 3, or 4; t is 0, 1, 2, 3, 4, 5, or 6; u is 1 or 2; and with the following provisos: a) A is not an unsubstituted, pyridyl, thienyl, furyl, or pyrrolyl; b) when R48 is nitro, A is other than furyl; c) when R48 is chloro, A is other than thienyl; and d) when Q is
;©-
Y and X are not both hydrogen.
2. A compound of claim 1 wherein A is
Figure imgf000070_0001
3. A compound of claim 2 wherein R2 is a) H, b) F, c) CI, d) Br, e) C1 3 alkyl, 0 N02, or g) *2 and R3 taken together are -0-(CH2)^-0-
Figure imgf000071_0001
R5 and Rg at each occurrence are the same or different and are a) Cj^ alkyl, or b) R5 and R6 taken together are -(CH2)jt-;
R7 is Cj.4 alkyl optionally substituted with one or more fluoro, chloro, bromo, or iodo;
R8 is a) H, or b) C^ alkyl optionally substituted with one or more fluoro, chloro, bromo, iodo, cyclopropyl, cyclopentyl, or cyclohexyl;
Rjø and R- at each occurrence are the same or different and are
Figure imgf000071_0002
d) cyclopentyl, or e) cyclohexyl;
Figure imgf000072_0001
4. A compound of claim 2 or 3 wherein R2 is H.
5. A compound of claim 2 wherein Rg is substituted in the para position.
6. A compound of claim 5 wherein
R2 is H;
Figure imgf000073_0001
a) C-|_ alkyl optionally substituted with one or more fluoro, chloro, bromo, or iodo, b) C2_4 alkenyl, c) -NR16R18, d) -N3, e) -N(R19)2, f) -NR16R19, g) -NR19R20,
Rg and Rg at each occurrence are the same or different and are a) C1 2 alkyl, or b) Rg and Rg taken together are -(CH2)j--;
R8 is a) H, or b) Cj_ alkyl optionally substituted with one or more fluoro, chloro, bromo, iodo, cyclopropyl, cyclopentyl, or cyclohexyl;
Figure imgf000073_0002
Figure imgf000074_0003
c) I; R20 is a physiologically acceptable cation;
R2ι and R22 at each occurrence are the same or different and are a) H, b) C^ alkyl, or c) -NR21R22 taken together are -(CH2)m-; i is 0, 1, or 2; j is 0, or 1; k is 3, 4, or 5; m is 4, or 5; and with the provisio that when R2 is H, R3 is other than -N02.
7. A compound of claim 1 wherein A is
Figure imgf000074_0001
8. A compound of claim 7 wherein R23 and
Figure imgf000074_0002
at each occurrence are the same or different and are H, or F.
9. A compound of claim 7 wherein Q is o-
10. A compound of claim 9 wherein Y is H with the provisio that X is other than H.
Figure imgf000075_0002
12. A compound of claim 7 wherein Q is
Figure imgf000075_0001
13. A compound of claim 12 wherein Y is H with the provisio that X is other than H.
14. A compound of claim 12 wherein X is
Figure imgf000076_0003
15. A compound of claim 7 wherein Q is
Figure imgf000076_0001
16. A compound of claim 7 wherein Q is
Figure imgf000076_0002
17. A compound of claim 7 wherein Q is 3^ X wherein B is an unsaturated 4-atom linker having one nitrogen and three carbons, Z is O, or S.
18. A compound of claim 17 which is a) furanopyridinyl, or b) thienopyridinyl.
19. A compound of claim 7 wherein Q is
Figure imgf000077_0001
20. A compound of claim 19 which is
* O~
21. A compound of claim 20 wherein R30 is methyl.
22. A compound of claim 21 which is (±)-N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l-yl)phenylj-5- isoxazolyljmethyljacetamide.
23. A compound of claim 7 wherein Q is
Figure imgf000077_0002
24. A compound of claim 23 wherein R38 is H, F, or CH3.
25. A compound of claim 23 wherein n is 0 and p is 1.
26. A compound of claim 23 wherein n and p taken together are 2.
27. A compound of claim 23 wherein n and p taken together are 3.
28. A compound of claim 23 wherein n and p taken together are 4.
29. A compound of claim 23 wherein E is a) NR39, b) -Sι O)if or c) O; wherein i is 0, 1, or 2.
30. A compound of claim 7 wherein Q is a diazinyl group optionally substituted with X and Y.
31. A compound of claim 30 which is
Figure imgf000078_0001
32. A compound of claim 7 wherein Q is a triazinyl group optionally substituted with X and Y.
33 A compound of claim 32 which is
Figure imgf000079_0001
34. A compound of claim 7 wherein Q is a quinolinyl group optionally substituted with X and Y.
35. A compound of claim 34 which is
Figure imgf000079_0002
36. A compound of claim 7 wherein Q is a quinoxalinyl group optionally substituted with X and Y.
37. A compound of claim 36 which is
Figure imgf000079_0003
38. A compound of claim 7 wherein Q is a naphthyridinyl group optionally substituted with X and Y.
39. A compound of claim 38 which is
Figure imgf000080_0001
40. A compound of claim 1 wherein A is
Figure imgf000080_0002
41. A compound of claim 40 wherein R44 is a) H, b) Cj.g alkyl, or c) R 4 and R45 taken together are
o
Figure imgf000080_0003
wherein h is 1, or 2.
42. A compound of claim 40 wherein R45 is an electron-withdrawing group.
43. A compound of claim 42 wherein R45 is -CN or -N02-
44. A compound of claim 40 wherein R46 is a) H, b) C1 3 alkyl, or c) phenyl.
45. A compound of claim 1 wherein A is a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and 0, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom, wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R4g.
46. A compound of claim 45 wherein A is, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl or furazanyl bonded directly via a carbon atom, or A is indolyl, benzo[b]thienyl, naphthio[2,3-bjthienyl, benzo[b]thiazolyl, benzo[b]imidazolyl or benzo[b]furanyl also bonded directly via a carbon atom of the 5-membered ring, wherein the heteroaromatic moiety is optionally substituted with one to three R4g.
47. A compound of claim 45 wherein R48 is a) carboxyl, b) fluoro, c) chloro, d) bromo, e) iodo, f) -CN, g) mercapto, h) formyl, i) CF3, j) -N02, k) Cj.4 alkoxy,
1) Cj 4 alkoxycarbonyl, m) C .4 alkythio, n) C1.4 acyl, o) -NR49 R50, p) Cj.4 alkyl optionally substituted with OH, C-^ alkoxy, C1-4 acyl, or -NR49R50, q) C2,4 alkenylphenyl optionally substituted with one or two R51, r) phenyl optionally substituted with one or two R51, s) pyridyl optionally substituted with one or two Rgi , t) thienyl optionally substituted with one or two R51, or
Figure imgf000082_0001
R49 and Rg0 at each occurrence are the same or different and are a) H, b) Cj^ alkyl, or c) R49 and R50 taken together with the nitrogen atom are morpholinyl, pyrrolidinyl, piperazinyl or piperidyl ring optionally substituted with, including on the free nitrogen atom, methyl, ethyl or acetyl;
Figure imgf000082_0002
c) phenyl; R54 is a) Cl alkyl, or b) phenyl optionally substituted with C1 4 alkyl, n is 0, 1, or 2 and with the following provisos: a) A is not an unsubstituted furyl, thienyl, pyrrolyl, b) when R48 is -N02, A is other than furyl, and c) when R48 is chloro, A is other than thienyl.
48. A compound of claim 1 wherein A is a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three Rgg.
49. A compound of claim 48 wherein A is cinnolinyl, pteridinyl, acridinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, phthalazinyl, quinolyl, isoquinolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, wherein the heteroaromatic moiety is optionally substituted with one to three Rgg.
50.
Figure imgf000083_0001
p) C1-4 alkyl optionally substituted with OH, Cχ_4 alkoxy, Cj_4 acyl, or
-NR5gR57, q) C2.4 alkenylphenyl optionally substituted with one or two R58, r) phenyl optionally substituted with one or two Rg8, s) pyridyl optionally substituted with one or two R58, t) thienyl optionally substituted with one or two R58, or
Figure imgf000084_0001
Rg6 and R57 at each occurrence are the same or different and are a) H, b) formyl, c) C1 3 alkyl, d) C^g acyl, e) phenyl,
0 cyclopropyl, g) cyclopentyl, h) cyclohexyl, or i) Rg and R57 taken together with the nitrogen atom are morpholinyl, pyrrolidinyl, piperazinyl or piperidyl ring optionally substituted with, including on the free nitrogen atom, phenyl, pyrimidyl, methyl, ethyl, or acetyl;
Figure imgf000084_0002
n) C^ acyl, o) phenyl, p) C .4 alkyl optionally substituted with OH, azido, C-^ alkoxy, C1 4 acyl, -NRggRgg, -SR67, -0-S02R68, or
Figure imgf000085_0001
Figure imgf000085_0002
Rgg and R66 at each occurrence are the same or different and are a) H, b) formyl, c) C^g alkyl, d) Cj.g acyl, e) phenyl, f) cyclopropyl, g) cyclopentyl, h) cyclohexyl, or i) Rgg and Rg7 taken together with the nitrogen atom are morpholinyl, pyrrolidinyl, piperazinyl or piperidyl ring optionally substituted with, including on the free nitrogen atom, phenyl, pyrimidyl, methyl, ethyl, or acetyl, j) -P(O)(OR70XOR71), or k) -S02-R72;
Rg7 is
Figure imgf000086_0001
CH,
Figure imgf000086_0002
a) Cj_g alkoxycarbonyl, or b) carboxyl; R70 and R71 at each occurrence are the same or different and are a) H, or b) Cχ 3 alkyl; and R72 is a) methyl, b) phenyl, or c) tolyl.
51. A compound of claim 1 wherein A is a β-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three Rgg.
52. A compound of claim 51 wherein R55 is the same as defined in claim 46.
53. A compound of claim 1 wherein A is
Figure imgf000087_0001
Figure imgf000087_0002
q) C1_g alkyl optionally substituted with OH, C^4 alkoxy, C1-4 acyl, -NR78R79, -N(phenylXCH2-CH2-OH), -0-CH(CH3)(OCH2CH3), or -0-phenyl-[para-NHC(=0)CH3J, r) C2.4 alkenylphenyl optionally substituted with R51, s) phenyl optionally substituted with Rg t) pyridyl optionally substituted with R51, or u) thienyl optionally substituted with R51; R51 is the same as defined in claim 43; and
R78 and R79 at each occurrence are the same or different and are a) H, b) Cj.3 alkyl, c) phenyl, or d) R78 and R79 taken together with the nitrogen atom are morpholinyl, pyrrolidinyl, piperazinyl or piperidyl ring optionally substituted with, including on the free nitrogen atom, methyl, ethyl, or acetyl.
55. A compound of claim 53 wherein R73, R74, R75, R7g, and R77 are hydrogen and the isoxazoline radical is bonded to the phenyl ring in position 5 or 6.
56. A compound of claim 1 wherein A is
Figure imgf000088_0001
c) carboxyl, d) C1 5 alkoxycarbonyl, e) C^g alkyl, f) C2.g alkenyl, wherein the substituents (e) and (f) can be optionally substituted with OH, fluoro, chloro, bromo, C^ alkoxy, C1_3 acyl, C^ alkylthio or
C^ alkoxycarbonyl, or phenyl optionally substituted with fluoro, chloro, bromo, g) phenyl optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, Cj.4 alkyl, C^ alkoxy, Cχ.4 acyl, C^ alkylthio, or C^ alkoxycarbonyl; h) -NR81R82,
Figure imgf000089_0003
Figure imgf000089_0001
R83R84 N→Q- . OG--
Figure imgf000089_0002
R81 and R 2 at each occurrence are the same or different and are a) cyclopropyl, b) cyclopentyl, c) cyclohexyl, d) phenyl, e) C-L.4 acyl, f) C^ alkyl optionally substituted with OH, C1 5 alkoxy which can be substituted with OH, g) pyridyl, pyrazinyl, pyrimidyl or phenyl optionally substituted with OH, CF3, fluoro, chloro, bromo, -N02, C1 3 alkoxy, -NR83R84, or
Figure imgf000090_0001
„ h) ^85 or
R86 C
i) \f N-(CH2)t-
V is a) 0, b) CH2, or c) NR87;
R8 and R 4 at each occurrence are the same or different and are a) H, or b) Cj.3 alkyl; R85 is a) OH, b) C1 3 alkoxy, or c) -NR88 R89;
R86 is a) H, or b) C1_5 alkyl optionally substituted with phenyl;
R87 is a) H, b) phenyl, or c) C1 4 alkyl optionally substituted by OH;
Rg8 and R89 at each occurrence are the same or different and are a) H, b) Cj.3 alkyl, c) cyclopropyl,
Figure imgf000091_0001
a) Cj. alkyl optionally substituted with Cj.g alkoxy or C-^g hydroxy, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidyl, pyrazinyl, quinolyl, which can in turn be substituted with one or two -N02, CF3, fluoro, chloro, bromo, -CN, OH, Cλ_4 alkyl, C-^alkoxy, or C^ acyl,
b) V / \ N,— ( ,rCιH_,2) >,—
c) phenyl, or d) pyridyl; R91 is a) C,.14 alkyl, b) C2.14 alkenyl, wherein the substituents (a) and (b) can be optionally substituted with C .4 alkoxycarbonyl, phenyl, thienyl, furyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, or pyridazinyl, c) phenyl, d) thienyl, e) furyl, f) pyrrolyl, g) imidazolyl, h) pyridinyl, i) pyrazinyl, j) pyrimidyl, or k) pyridazinyl; wherein the substituents (c) and (k) can be optionally substituted with carboxyl, halo, -CN, formyl, CF3, -N02, C^ alkyl, Cχ_4 alkoxy, C^ acyl, C^ alkylthio, or Cj_4 alkoxycarbonyl; R92 and R93 at each occurrence are the same or different and are a) H, b) phenyl, c) Cj.4 alkyl, or d) benzyl; R94 and Rg5 at each occurrence are the same or different and are a) H,
Figure imgf000092_0001
R97 is fi CΘ- a) morpholinyl, b) OH, or c) Cj.g alkoxy; j is 0, or 1; t is 0, 1, 2 or 3; and u is 1, or 2.
58. A compound of claim 55 wherein R7g, R76 and R77 are hydrogen and the isoxazoline radical is bonded to the phenyl ring in position 5 or 6.
59. A compound of the formula I which is
Figure imgf000093_0001
60. A compound of claim 1 wherein R^ is H, methyl, chloromethyl, dichloro- methyl, or methoxy.
61. A compound of claim 1 which is
1. (±)-N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l-yl)phenyl]-5- isoxazolyljmethyljacetamide;
2. tert-Butyl 4-[4-[5-[(acetylamino)methylj-4,5-dihydro-3-isoxazolyl]phenylj-3,6- dihydro- l(2H)-pyridinecarboxylate;
3. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l- yl)phenylj-5-isoxazolyl]methyl]acetamide;
4. (±)-N-[[4,5-Dihydro-3-[3,5-difluoro-4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l- yl)phenyl]-5-isoxazolyljmethyl]acetamide; 5. (±)--V-[[4,5-Dihydro-3-[4-[ l-(4-oxo-2-thiazolinyl)-4-piperidinyl j-3,5- difluorophenyl]-5-isoxazolyl]methyl]acetamide;
6. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4- yljphenylj-5-isoxazolyl]methyljacetamide;
7. (±)-N-[[4,5-Dihydro-3-t4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4-ylj- 3-fluorophenylj-5-isoxazolyl]methyljacetamide;
8. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-2,3,6,7-tetrahydro-lH-azepin-4-yl]- 3,5-difluorophenyl]-5-isoxazolyl]methyl]acetamide;
9. N-[[4,5-Dihydro-3-[4-(l,2,3,6-tetrahydropyridinyl)phenyl]-5-isoxazolyl]- methyljacetamide; 10. (±)-N-[[4,5-Dihydro-3-[4-[ l-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3- fluorophenyl]-5-isoxazolyl]methyl]acetamide;
11. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-3,6-dihydro-2H-pyridin-4-yl]-3,5- difluorophenyl]-5-isoxazolyl]methyl]acetamide;
12. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinyl]phenyl]-5- isoxazolyljmethyljacetamide;
13. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinylj-3-fluorophenyl]-5- isoxazolyljmethyljacetamide;
14. (±)-N-[[4,5-Dihydro-3-[4-[l-(hydroxyacetyl)-4-piperidinyl]-3,5-difluorophenyl]- 5-isoxazolyl]methyl]acetamide;
15. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide;
16. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-pyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide;
17. (±)-N-[[4,5-Dihydro-3-t4-(tetrahydro-2H-pyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide; 18. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide;
19. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide;
20. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-pyran-4-yl)-3,5-difluorophenylj-5- isoxazolyljmethyljacetamide;
21. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyljmethyl jacetamide ;
22. (±)-iV-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenylj-5- isoxazolyljmethyljacetamide; 23. (±)-ΛT-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide;
24. (±)-N-[[4,5-Dihydro-3-t4-(3,6-dihydro-2H-thiopyran-4-yl)phenylj-5- isoxazolyljmethyljacetamide;
25. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide;
26. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide;
27. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenylj-5- isoxazolyljmethyljacetamide S-oxide; 28. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenylj-5- isoxazolyljmethyljacetamide S-oxide;
29. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide S-oxide;
30. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
31. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
32. (±)-N-[[4,5-Dihydro-3-[4-(tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
33. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenylj-5- isoxazolyljmethyljacetamide S-oxide;
34. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxazolyljmethyljacetamide S-oxide;
35. (±)-N-[t4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenylj-5- isoxazolyljmethyljacetamide S-oxide; 36. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-5- isoxazolyljmethyljacetamide S,S-dioxide;
37. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5- isoxaz olyljmethyl] acetamide S , S-dioxide;
38. (±)-N-[[4,5-Dihydro-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenylj-5- isoxazolyljmethyljacetamide S,S-dioxide;
39. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(carboxymethyl)-3-(3- methyl)azetidinyljphenyl]-5-isoxazolyl]methyl]acetamide;
40. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(formyl)-3-(3-methyl)azetidinyl]phenylj-5- isoxazolyljmethyljacetamide; 41. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[ l-(carboxymethyl)-3-azetidinyl]phenyl]-5- isoxazolyljmethyljacetamide;
42. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(formyl)-3-azetidinyl]phenylj-5- isoxazolyljmethyljacetamide;
43. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(hydroxyacetyl)-3-pyrrolidinyljphenylj-5- isoxazolyljmethyljacetamide;
44. (±)-N-[[4,5-Dihydro-3-[3-fluoro-4-[l-(formyl)-3-pyrrolidinyl]phenylj-5- isoxazolyljmethyljacetamide;
45. (±)-N-[[4,5-Dihydro-3-t4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-yl]phenylj-5-isoxazolyljmethyl]acetamide; 46. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-yl]-3-fluorophenylj-5-isoxazolyl]methyljacetamide;
47. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-3,6-dihydro-2H- pyridin-4-ylj-3,5-difluorophenyl]-5-isoxazolyl]methyljacetamide;
48. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4- piperidinyljphenyl]-5-isoxazolyl]methyljacetamide;
49. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4-piperidinyl]-3- fluorophenyl]-5-isoxazolyl]methyl]acetamide;
50. (±)-N-[[4,5-Dihydro-3-[4-[l-(5-methyl-l,3,4-thiadiazol-2-yl)-4-piperidinylj-3,5- difluorophenyl]-5-isoxazolyl]methyl]acetamide;
51. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4- yl]phenyl]-5-isoxazolyl]methyljacetamide;
52. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4-ylj-3- fluorophenylj-5-isoxazolyljmethyl]acetamide;
53. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-3,6-dihydro-2H-pyridin-4-yl]- 3,5-difluorophenylj-5-isoxazolyljmethyl]acetamide; 54. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-4-piperidinyl]phenyl]-5- isoxazolyljmethyljacetamide;
55. (±)-N-[[4,5-Dihydro-3-[4-[l-(4-oxo-2-thiazolinyl)-4-piperidinyl]-3-fluorophenylj- 5-isoxazolyljmethyl]acetamide;
56. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(hydroxyacetyl)-4-pyridinyl]phenylj- 5-isoxazolyljmethyl]acetamide;
57. (R)-N-[[4,5-Dihydro-3-[4-tl,2,3,6-tetrahydro-l-(hydroxyacetyl)-4- pyridinyljphenyl]-5-isoxazolyljmethyl]acetamide;
58. Methyl 4-[4-[5-[(acetylamino)methylj-4,5-dihydro-3-isoxazolyljphenylj-3,6- dihydro-l(2H)-pyridinecarboxylate; 59. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(acetyl)-4-pyridinyljphenyl]-5- isoxazolyljmethyljacetamide; or 60. (R)-N-[[4,5-Dihydro-3-[4-(4-pyridinyl)phenylj-5-isoxazolyljmethyl]acetamide.
62. A compound of claim 1 which is 1. N-[[4,5-Dihydro-3-[4-(4-methoxy-5-oxo-l,3,6-cycloheptatrien-l-yl)phenyl]-5- isoxazolyljmethyljacetam.de;
2. tert-Butyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3-isoxazolyljphenyl]-3,6- dihydro-l(2H)-pyridinecarboxylate;
3. N-[[4,5-Dihydro-3-[4-(l,2,3,6-tetrahydropyridinyl)phenyl]-5-isoxazolylj- methyljacetamide;
4. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(hydroxyacetyl)-4-pyridinyljphenylj- 5-isoxazolyljmethyljacetamide;
5. (R)-N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(hydroxyacetyl)-4- pyridinyl]phenylj-5-isoxazolyl]methyl]acetamide; 6. Methyl 4-[4-[5-[(acetylamino)methyl]-4,5-dihydro-3-isoxazolyljphenylj-3,6- dihydr o- l(2H)-pyridinecarboxylate ;
7. N-[[4,5-Dihydro-3-[4-[l,2,3,6-tetrahydro-l-(acetyl)-4-pyridinyl]phenyl]-5- isoxazolyljmethyljacetamide; or
8. (R)-N-[[4,5-Dihydro-3-[4-(4-pyridinyl)phenylj-5-isoxazolyl]methyl]acetamide.
63. A method for treating microbial infections in patients which comprises administering to a patient in need thereof an effective amount of a compound of formula I.
PCT/US1997/013934 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobials WO1998007708A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP10510781A JP2000516245A (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antibacterial agents
DE69716925T DE69716925T2 (en) 1996-08-21 1997-08-15 ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIMICROBE
EP97937156A EP0920421B1 (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobials
SI9730449T SI0920421T1 (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobials
DK97937156T DK0920421T3 (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobial agents
AU39736/97A AU3973697A (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobials
AT97937156T ATE227277T1 (en) 1996-08-21 1997-08-15 ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIMICROBES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2428796P 1996-08-21 1996-08-21
US60/024,287 1996-08-21

Publications (1)

Publication Number Publication Date
WO1998007708A1 true WO1998007708A1 (en) 1998-02-26

Family

ID=21819822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013934 WO1998007708A1 (en) 1996-08-21 1997-08-15 Isoxazoline derivatives useful as antimicrobials

Country Status (10)

Country Link
US (2) US5990136A (en)
EP (1) EP0920421B1 (en)
JP (1) JP2000516245A (en)
AT (1) ATE227277T1 (en)
AU (1) AU3973697A (en)
DE (1) DE69716925T2 (en)
DK (1) DK0920421T3 (en)
ES (1) ES2186916T3 (en)
PT (1) PT920421E (en)
WO (1) WO1998007708A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054161A1 (en) * 1997-05-30 1998-12-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
WO1999041244A1 (en) * 1998-02-13 1999-08-19 Pharmacia & Upjohn Company Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
WO1999043671A1 (en) * 1998-02-25 1999-09-02 Pharmacia & Upjohn Company Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
US6069145A (en) * 1996-01-27 2000-05-30 Zeneca Limited Piperazinonephenyloxazolidinone derivatives and their use as antibacterial agents
US6110936A (en) * 1996-05-11 2000-08-29 Zeneca Limited 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents
US6194441B1 (en) 1997-08-22 2001-02-27 Zeneca Ltd. Oxazolidinone derivatives and their use as antibacterial agents
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
EP1107756A1 (en) * 1998-08-24 2001-06-20 Bristol-Myers Squibb Company Novel isoxazolinone antibacterial agents
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
WO2002053523A1 (en) * 2000-12-26 2002-07-11 Research Foundation Itsuu Laboratory Tropolone derivative
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
US6495551B1 (en) 1997-11-29 2002-12-17 Michael John Betts Substituted phenyloxazolidinones and their use as antibiotics
WO2003035073A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
US6605630B1 (en) 1997-08-22 2003-08-12 Syngenta Limited Antibiotic oxazolidinone derivatives
US6617339B1 (en) 1998-06-05 2003-09-09 Syngenta Limited Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
US6689769B2 (en) 2000-12-21 2004-02-10 Pharmacia & Upjohn Company Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
WO2005082900A2 (en) * 2004-01-28 2005-09-09 Pharmacia & Upjohn Company Llc Oxazolidinone amidoximes as antibacterial agents
US7141583B2 (en) 2000-04-25 2006-11-28 Astrazeneca Ab Oxazolidinone derivatives with antibiotic activity
AU2013327663B2 (en) * 2012-10-03 2016-03-10 Shell Internationale Research Maatschappij B.V. Optimizing performance of a drilling assembly
WO2021000297A1 (en) * 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
AR038536A1 (en) * 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
BRPI0407304A (en) * 2003-02-07 2006-01-10 Warner Lambert Co Antibacterial agents
BRPI0407252A (en) * 2003-02-07 2006-01-31 Warner Lambert Co Antibacterial agents.
US7304050B2 (en) * 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
JP2008509125A (en) * 2004-08-06 2008-03-27 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Oxindole oxazolidinone as an antibacterial agent
KR101508862B1 (en) * 2010-08-05 2015-04-07 조에티스 엘엘씨 Isoxazoline derivatives as antiparasitic agents
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769295A (en) * 1967-08-26 1973-10-30 Ciba Geigy Corp Nitrofuryl derivatives of 5-substituted isoxazolines
US4283403A (en) * 1976-06-14 1981-08-11 Eli Lilly And Company Substituted isoxazolines for control of plant phytopathogens
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1994013649A1 (en) * 1992-12-08 1994-06-23 The Upjohn Company Tropone-substituted phenyloxazolidinone antibacterial agents
WO1995014680A1 (en) * 1993-11-26 1995-06-01 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
EP0693491A1 (en) * 1994-07-20 1996-01-24 Bayer Ag Oxazolidinones substituted by 5-membered heteroaryl group as antibacterial medicine
EP0694543A1 (en) * 1994-07-20 1996-01-31 Bayer Ag 6-membered N-heteroaryloxazolidinones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769295A (en) * 1967-08-26 1973-10-30 Ciba Geigy Corp Nitrofuryl derivatives of 5-substituted isoxazolines
US4283403A (en) * 1976-06-14 1981-08-11 Eli Lilly And Company Substituted isoxazolines for control of plant phytopathogens
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1994013649A1 (en) * 1992-12-08 1994-06-23 The Upjohn Company Tropone-substituted phenyloxazolidinone antibacterial agents
WO1995014680A1 (en) * 1993-11-26 1995-06-01 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
EP0693491A1 (en) * 1994-07-20 1996-01-24 Bayer Ag Oxazolidinones substituted by 5-membered heteroaryl group as antibacterial medicine
EP0694543A1 (en) * 1994-07-20 1996-01-31 Bayer Ag 6-membered N-heteroaryloxazolidinones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMI S. GHABRIAL ET AL: "Synthesis of biheteroaromatic compounds via the isoxazoline route", ACTA CHEMICA SCANDINAVICA. SERIES B - ORGANIC CHEMISTRY AND BIOCHEMISTRY., vol. 41, 1987, COPENHAGEN DK, pages 426 - 434, XP002045744 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069145A (en) * 1996-01-27 2000-05-30 Zeneca Limited Piperazinonephenyloxazolidinone derivatives and their use as antibacterial agents
US6350775B1 (en) 1996-05-11 2002-02-26 Zeneca Limited 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents
US6110936A (en) * 1996-05-11 2000-08-29 Zeneca Limited 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents
US6342513B1 (en) 1997-05-30 2002-01-29 Pharmacia And Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6218413B1 (en) 1997-05-30 2001-04-17 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6362189B1 (en) 1997-05-30 2002-03-26 Pharmacia And Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6537986B2 (en) 1997-05-30 2003-03-25 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl funtionality
WO1998054161A1 (en) * 1997-05-30 1998-12-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6194441B1 (en) 1997-08-22 2001-02-27 Zeneca Ltd. Oxazolidinone derivatives and their use as antibacterial agents
US6605630B1 (en) 1997-08-22 2003-08-12 Syngenta Limited Antibiotic oxazolidinone derivatives
US6495551B1 (en) 1997-11-29 2002-12-17 Michael John Betts Substituted phenyloxazolidinones and their use as antibiotics
WO1999041244A1 (en) * 1998-02-13 1999-08-19 Pharmacia & Upjohn Company Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
US6069141A (en) * 1998-02-13 2000-05-30 Pharmacia & Upjohn Company Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
WO1999043671A1 (en) * 1998-02-25 1999-09-02 Pharmacia & Upjohn Company Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
US6617339B1 (en) 1998-06-05 2003-09-09 Syngenta Limited Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
EP1107756A4 (en) * 1998-08-24 2003-02-26 Bristol Myers Squibb Co Novel isoxazolinone antibacterial agents
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
EP1107756A1 (en) * 1998-08-24 2001-06-20 Bristol-Myers Squibb Company Novel isoxazolinone antibacterial agents
US7081538B1 (en) 1999-12-03 2006-07-25 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
US7141583B2 (en) 2000-04-25 2006-11-28 Astrazeneca Ab Oxazolidinone derivatives with antibiotic activity
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
US6689769B2 (en) 2000-12-21 2004-02-10 Pharmacia & Upjohn Company Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
US6869965B2 (en) 2000-12-21 2005-03-22 Pharmacia & Upjohn Company Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
AU2002222682B8 (en) * 2000-12-26 2008-05-29 Research Foundation Itsuu Laboratory Tropolone Derivatives
US7259187B2 (en) 2000-12-26 2007-08-21 Research Foundation Itsuu Laboratory Tropolone derivatives
AU2002222682B2 (en) * 2000-12-26 2007-12-13 Research Foundation Itsuu Laboratory Tropolone Derivatives
WO2002053523A1 (en) * 2000-12-26 2002-07-11 Research Foundation Itsuu Laboratory Tropolone derivative
US7022705B2 (en) 2001-10-25 2006-04-04 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
WO2003035073A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
WO2005082900A3 (en) * 2004-01-28 2006-02-16 Pharmacia & Upjohn Co Llc Oxazolidinone amidoximes as antibacterial agents
WO2005082900A2 (en) * 2004-01-28 2005-09-09 Pharmacia & Upjohn Company Llc Oxazolidinone amidoximes as antibacterial agents
AU2013327663B2 (en) * 2012-10-03 2016-03-10 Shell Internationale Research Maatschappij B.V. Optimizing performance of a drilling assembly
WO2021000297A1 (en) * 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
WO2021000684A1 (en) * 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
CN114341119A (en) * 2019-07-03 2022-04-12 默沙东公司 Compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
DK0920421T3 (en) 2003-03-10
EP0920421A1 (en) 1999-06-09
PT920421E (en) 2003-03-31
DE69716925D1 (en) 2002-12-12
DE69716925T2 (en) 2003-09-11
EP0920421B1 (en) 2002-11-06
ES2186916T3 (en) 2003-05-16
AU3973697A (en) 1998-03-06
US6093736A (en) 2000-07-25
ATE227277T1 (en) 2002-11-15
JP2000516245A (en) 2000-12-05
US5990136A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
US5990136A (en) Isoxazoline derivatives useful as antimicrobials
EP1054874B1 (en) Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
US6218413B1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
RU2175324C2 (en) Phenyloxazolidinones having c-c-bond with 4-8-membered heterocyclic rings
EP0874852B1 (en) Oxazolidinone antibacterial agent with tricyclic substituents
US6255304B1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
JP2007505890A (en) Acyloxymethyl carbamate prodrugs of oxazolidinones
WO2000032599A1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
WO1999043671A1 (en) Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
US20040014967A1 (en) Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
US6281210B1 (en) Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent
US20040127530A1 (en) Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
US6825225B2 (en) Bicyclic isoxazolinones as antibacterial agents
US20040204463A1 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
WO2006051408A1 (en) Oxazolidinone derivatives as antimicrobials
WO2003062231A1 (en) Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 510781

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997937156

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997937156

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1997937156

Country of ref document: EP